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ABSTRACT
The focus of this thesis is the role of dengue virus in the induction of chemokines.
Dengue virus (DENV) occurs as four distinct serotypes , called DENV 1 , 2 , 3 , and 4.
Symptomatic DENV infection ranges from a self limited febrile ilness , dengue fever
(DF), to a more severe disease, dengue hemorrhagic fever/dengue shock syndrome
(DHF/DSS). DHF is characterized by increased capilary permeability resulting in
decreased plasma volume , which may be accompanied by hemorrhagic manifestations.
Many factors including T cell cross reactivity, viral burden , antibody dependent
enhancement and induction of chemokines and cytokines have been reported in DHF and
may playa role in the pathogenesis of DENV infection.
Cytokines have been shown to modulate endothelial cell permeability (1-3).
Recent studies have shown that DENV-infected endothelial cells secrete the chemokine
interleukin (IL)- in vitro (4). In addition , the permeability of an endothelial cell
monolayer was found to be increased by interleukin-S (IL- S) in vitro (5). This thesis
examines the effects of DEN2V infection on the induction of chemokines , and
specifically, which DEN2V viral protein(s) are involved in the induction of IL-
The chemokine induction profile following DEN2V infection was initially
assessed in various cell lines that may represent potential targets in vivo, including
monocytes , liver cells and endothelial cells. We hypothesized that distinct profiles of
chemokine secretion can be induced by DEN2V infection of various cell types in vitro.
We found RANTES (Regulated upon Activation , Normal T cell Expressed and Secreted)
and IL-S were induced in two of the five cell lines. DEN2V infection of primary
monocyte-derived dendritic cells induced RANTES and IL-S along with macrophage
,\, ''-'"
inflammatory protein- l ex (MIP- I ex), MIP- and monocyte chemoattractant protein-
(MCP- I) but at an earlier time post infection than in the cell lines. These results showed
that DEN2V infection induces distinct chemokine profiles in many cell types. 
addition , monocytic-derived DCs can secrete chemokines upon infection with DEN2V.
Characterization of the signaling pathways induced by DEN2V revealed that
DEN2V induction of chemokines in human embryonic kidney (HEK293A) cells is
mainly through the nuclear factor kappaB (NFKB) pathway, as previously reported for
endothelial cells and 293T cells (4 , 6). Alternatively, the liver cell line (HepG2) activated
mainly activator protein (AP)- l. In addition , DENV infection can induce the activation
of the interferon-stimulated response element (ISRE) driven promoter.
IL-8 has been shown to have multiple effects on the immune system ranging from
recruiting cells to the site of infection to countering the antiviral effects of type I
interferon (IFN) (7 , 8). Previous reports have' shown that viral proteins can induce
chemokines such as seen with IL-8 induction with the nonstructural protein 5A (NS5A)
and core proteins from hepatitis C virus (9 , 10). We hypothesized that protein(s) from
DENV could induce chemokine production. The expression of DENV proteins was
analyzed for effects on IL-8 and RANTES production in HEK293A cells. The effects of
viral replication on IL-8 and RANTES induction were also analyzed using a DENV
replicon that contains genes for the capsid protein and the nonstructural proteins.
Transfection of plasmids expressing NS5 or the DEN2V replicon induced the expression
and secretion of IL-8 but not RANTES. We attributed the lack of RANTES induction to
the inability of NS5 or the DEN2V replicon to induce transcription from the ISRE driven
promoter. We also found that NS5 and the DEN2V replicon induced IL-8 mainly
"':'
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through the CCAA T/enhancer binding protein (c/EBP) and AP- l pathways. The profile
of transcription factor activation is different from what was seen with DENY infection of
HEK293A cells and suggests that the transient expression of the NS5 protein and the
replication and/or translation of the DEN2V genome use different pathways than viral
infection to induce IL-
In addition , we found that the expression of prM- , known to produce virus-like
particles , could induce IL-8 secretion and activate transcription from the IL-8 promoter.
As with the expression of NS5 , RANTES was not induced. Analysis of the transcription
factors involved in IL-8 induction using luciferase reporter constructs indicated that
expression of prM-E induced transcription of IL-8 through NFKB , AP- l and c/EBP
similar to what was seen with DEN2V infection of HEK293A cells. These results suggest
that production of virions or virus-like particles induce IL-8 but that another mechanism
in the viral life cycle is responsible for the InduCtion of RANTES expression by DEN2V
infection.
We were also interested in the effects of drugs that have been used previously to
inhibit cytokine or chemokine production on chemokine induction during DEN2V
infection. We hypothesized that pharmacological inhibitors of cytokines wil inhibit
secretion of chemokines in DEN2V infected cells. We found that the pharmacological
inhibitors SB203580 and rolipram enhanced chemokine production in a DEN2V infected
liver cell line (HepG2), whereas dexamethasone had the same effect in a kidney epithelial
cell line (HEK293A). We conclude that drugs that inhibit signaling pathways involved in
cytokine production in other experimental systems can have variable effects on
chemokine induction in different cell types during DEN2V infection.
. .. , " -
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The data generated in this thesis extend our understanding of how DEN2V
manipulates the host cell during viral infection to produce chemokines and perhaps
enhance viral propagation and dissemination through the induction of IL-8. In addition
this study provides insight into the variable effects pharmacological drug treatment may
have on disease progression during DENV infection. These results increase our
understanding of DEN V pathogenesis and may be helpful in finding better strategies for
treatment and prevention.
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CHAPTER I:
INTRODUCTION
A. EPIDEMIOLOGY
Dengue is one of the most important human viral diseases transmitted by
arthropod vectors in terms of morbidity and mortality. Currently approximately 50-100
million dengue infections and 500 000 cases of DHF occur annually. Of these cases
around 24 000 deaths occur depending on the epidemic activity. Over half the world'
population lives in areas that are at risk for dengue transmission (11 , 12).
Dengue viruses are transmitted to humans through the bite of infected female
mosquitoes of the genus Aedes. The primary mosquito vector isAedes aegypti (13).
Mosquitoes can acquire the virus while feeding on the blood of an infected person. After
virus incubation for 8- 10 days , an infected mosquito is capable of transmitting the virus
to susceptible individuals for the rest of the mosquito s life. A. aegypti feed on humans
and breed in collections of clean water (storage jars , containers , etc.). Only the females
seek blood meals , and they feed primarily during the day (14).
The geographical distribution of DENV is limited to regions where Aedes
mosquitoes are present; these are generally tropical and subtropical regions (15) (Figure
1). Most countries in central and south America had eradicated A. aegypti in the 1950s
and 1960s due to efforts of the Pan American Health Organization. Unfortunately, these
efforts were terminated , and by the late 1970s A. aegypti had reinfested many countries
(11). Along with the increase in the mosquito population was the introduction of new
strains and serotypes of DENV followed by the emergence of DHF (11 , 16). Several
factors have been implicated in the global resurgence of DEN V : failure to control the
Aedes mosquito population , increased airplane travel to dengue endemic areas
uncontrolled urbanization , and unprecedented population growth (11).
World Distribution of Dengue - 2000
.. \ '\. .. 
Mas infeskd with A€$ crtt
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Figure 1- 1. World distribution of dengue and Aedes aegypti in 2000.
www.cdc.gov/ncidod/dvbid/dengue/map-distribution-2000.htm
B. CLINICAL DISEASE IN HUMANS
1. Dengue Disease
There are four serotypes of DENV (1, 2 , 3 , and 4). Infection with one serotype
wil give the host life long immunity to that serotype, but only transient cross protective
immunity to the other three serotypes. Dengue virus infections are often asymptomatic
but infection with any serotype can result in undifferentiated fever, dengue fever (DF) or
dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) (12).
Classical DF symptoms include an abrupt onset of high fever lasting 5-7 days that
can return to normal and then spike again ('saddleback fever ), severe headache , retro-
orbital pain , myalgia, nausea, vomiting, rash, neutropenia, leukopenia and
thrombocytopenia (11 , 12 , 16). Infants and young children may have undifferentiated
fever with a maculopapular rash whereas older children and adults tend to have either a
mild febrile ilness or the classical DF (11).
DHF occurs in -2% of individuals that are infected a second time with a different
serotype of DEN V (Figure 1-2). Generally, symptoms are similar to DF initially.
However, at the time of defervesence the patient can progress to the more severe disease
DHF. Clinical findings of DHF at the time of defervesence include plasma leakage
which results in hemoconcentration, and thrombocytopenia (11). A system for grading
the severity of DHF has been defined by the World Health Organization (WHO) (12).
Grade I DHF requires all of the following findings: fever, severe thrombocytopenia
(platelet count .:100 000 cells/f.l), plasma leakage , and a positive tourniquet test. In
addition to these minimal criteria for DHF, Grade II DHF includes spontaneous bleeding.
Grades II and IV are considered to be DSS in which hypovolemia and circulatory shock
develop (12 , 17).
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Figure 1-2. Frequency of dengue fever and dengue hemorraghic fever in children
ages 1-14. DF is more prevalent than the more severe forms of DENV disease
DHF/DSS. However, the incidence of DHF/DSS increases during a secondary infection.
Figure is based on data from reference (18) and the portrayal is adapted from reference
(19).
2. Pathological findings
Although DHF is classified by plasma leakage, no destruction of vascular
endothelial cells is evident in autopsy tissue samples (20). Therefore , plasma leakage is
thought to be likely due to altered vascular permeability rather than to structural
destruction of endothelial cells (20). The mechanism of DEN V induced plasma leakage is
stil undefined , but the process is thought, based on in vitro studies , to be mediated by
proinflammatory cytokines and chemokines such as IL- , tumor necrosis factor a
(TNFa), IL-8 and RANTES (21).
DHF is frequently associated with moderate degrees of hepatic functional
abnormalities and can show characteristics typical of acute hepatitis. Most changes in the
liver are focal and mild with fatty changes, formation of Councilman bodies and
degeneration of hepatocytes and Kupffer cells (22 , 23). In addition , the levels of aspartate
transaminase (AST) and alanine transaminase (AL T) are significantly higher in patients
with more severe grades of DHF (24 , 25).
c. PATHOGENESIS OF INFECTION
Approximately 80 - 90% of DHF cases occur during a second DENV infection
(18 , 26 , 27). DHF commonly occurs in areas where multiple serotypes of dengue virus
are circulating. The hallmark sign of DHF is plasma leakage. Plasma leakage occurs near
the time of defervesence and after peak viremia (28). Generally, the plasma leakage is
short-lived without tissue damage. These clinical features suggest that plasma leakage
following DENV infections is due to an immunologic response rather than a direct viral
effect. Some of the factors that have been associated with dengue pathogenesis include
levels of viremia, antibody, cytokine and T-cell responses.
1. Virulence of viral strains
Rico-Hesse et al found an association of DHF in the American countries -
Venezuela, Brazil , Colombia and Mexico - with the introduction of a Southeast Asian
genotype of dengue type 2 virus (DEN2V) in the 1990s (29). In addition, they found no
evidence that the ' American ' genotype which has only been associated with DF was stil
present in areas that experienced the introduction of strains of the Southeast Asian
genotype (29). Recently, the same research group reported a greater production of viral
progeny from DCs that were infected with some of the Southeast Asian genotype viruses
when compared to the American genotype viruses (30). These results suggest that
viruses with the potential to cause DHF (Southeast Asian genotype) can replicate more
efficiently in DCs , which may give them an advantage over their more benign
counterparts (American genotype) by increasing the levels of viremia in the human host.
2. Antibody Dependent Enhancement
Antibody dependent enhancement (ADE) is speculated to playa key part in the
pathogenesis of severe infections during secondary DEN V infections. Antibodies to
DENV are present in the blood due to primary infection. ADE is thought to occur when
circulating antibody is at subneutralizing concentrations (15 , 31-37). During secondary
infection , subneutralizing antibodies recognize the DENV and form complexes. The
constant fragment (Fc) portion of the antibody is recognized by cells expressing Fc
receptors (FcR) such as monocytes (38). The binding of antibody-virus complexes to the
FcR allows enhanced uptake of virus , resulting in an increased number of cells being
infected by the virus (39). The antibodies that mediate ADE in dengue are primarily
directed against the E protein (40).
3. Complement activation
A marked reduction of complement proteins and a concurrent increase in
complement fragments was observed in DHF/DSS , and the degree of complement
activation correlated with the severity of the disease (41). Complement activation
assessed by an increase in complement fragments C3a and C5a, preceded onset of shock
in DENV patients in another study (42). The complement fragments C3a and C5a are
proinflammatory molecules involved in activation and chemotaxis of myeloid cells
expressing anaphylatoxin receptors C3aR and C5aR/CD88 (43). C5a is a potent
chemoattractant of neutrophils and monocytes. C3a is known to induce histamine release
from mast cells , which enhances vascular permeabilty (6 43). It has also been
demonstrated that the complex C5b-9 forms on the surface of endothelial cells and can
create gaps in the endothelium without cytolysis (44). Avirutnan et al. found that
serotype cross-reactive Abs to DENV could deposit C3 and C5b-9 on dengue infected
endothelial cells in vitro and that this occured independent of DENV - induced cell death
(6). These mechanisms have been been proposed to contribute to vascular leakage in
DHF (6).
4. T lymphocytes
Cytotoxic T cells (CTLs) have been shown to play an important role in viral
clearance from the host (45 46). Virus-specific CTLs directly lyse virus-infected antigen
presenting cells. Additionally, these CTLs can release cytokines such as IFNy upon
activation. Initially, CD8+ T cells were thought to be the only cytotoxic T cells.
However, some CD4+ T cells have also shown cytotoxic activity (47-49). It is stil
thought that CD8+ T cells are the main mechanism for clearance and recovery from viral
infections.
CTLs directly lyse cells through the perforinlgranzyme pathway. Perforin forms
pores in the target cell causing a loss of plasma membrane integrity and , subsequently,
cell lysis. CTLs also express Fas ligand, which can interact with Fas that is expressed on
antigen presenting cells (50). This interaction induces apoptosis of the target cell.
A predominant Thl response , stimulating CTL activity, is thought to occur during
the initial stage of dengue infection, as characterized by higher serum concentrations of
TNFa, IL- , IL- , and IFNy (51). A Th2 response , which is involved in antibody-
mediated responses , tends to appear later in DENV infection and is characterized by an
increase in IL- lO, IL-5 and IL-4levels (51). Severe cases of DEN V infections had
increased levels oflL- lO, IL- , IL- 18 and TGF in several studies , whereas high levels
of IL- 12 were found in patients with less severe dengue disease (52-54). These results
suggest that predominant Th2 response can increase the severity of DENV infection.
It has been proposed that T cells play an important role in the
immunopathogenesis of DENY disease (55-58). Primary DENY infection induces the
development of DENY -specific memory CD4+ and CD8+ T cells. In response to in vitro
stimulation with DENY antigens , a memory DENV -specific CD4+ and CD8+ CTL
response are detected (57). CD4+ T cells produce IFNy, TNFa, and TNF upon
stimulation in vitro. IFNy has been shown to increase expression of Fcy receptors on
monocytes , which can further augment DENY infection of monocytes by virus-antibody
complexes (59). In addition, activated DENV specific CD4+ T cell clones were able to
lyse non antigen presenting HepG2 hepatoma cells , suggesting a role for T cell immune
responses in liver injury during DENY infections (57).
Kurane et al have shown that DENY -specific cytotoxic T cells can be detected in
human volunteers who received live attenuated monovalent dengue vaccines as a primary
infection (60). Characterization of the DENV:specific CD8+ T cells found that some of
the T cells were cross-reactive with other serotypes of dengue virus , indicating the
potential for them to be activated during a secondary infection (28 , 58 , 61). Studies
looking at epitopes of DENV proteins from all four serotypes and their ability to activate
memory CD8+ T cells found that the epitopes that elicited the predominant responses
were contained within the NS3 and NSl/NS2A proteins (62). Other epitopes that
activated memory CD8+ T cells were found within the E and prM proteins (62). These
studies show that dengue specific cross-reactive T cells can be activated during a
secondary infection.
Markers of T cell activation , including levels of soluble CD4, soluble CD8
soluble IL-2 and soluble TNFR , are elevated in DENV infected patients with acute
disease (63-66). Increased production of cytokines induding IL- , IL- , IL- , IFN Y
and TNFa have also been associated with more severe DENY disease (52 67).
These results suggest that immune activation contributes to the pathogenesis of DENY.
Based on the in vitro evidence previously mentioned regarding T cell activation
ADE and complement activation , our laboratory has proposed a model for DENY
pathogenesis. It is proposed that antibody-dependent enhancement of DENY infection is
likely to result in an increased number of DENY infected cells during a secondary
infection. This could increase the number of antigen presenting cells and thereby
increase the number of activated T cells. In secondary infections, cross-reactive memory
T cells generated during the primary infection are reactivated earlier and more intensely
than naive T cells. This contributes to the higher level of T cell activation seen during
secondary DENV infections (Figure 1-3).
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Figure 1-3. Model for DHF pathogenesis. Memory DENV-specific T cells are
activated following a secondary infection of the host with a different DENV serotype.
The activated memory T cells rapidly express cytokines such as TNFa and IFNy. In
addition, DENV specific antibodies can increase the viral burden of virus-infected cells
expressing Fcy receptors by ADE. The increased number of viral antigen presenting
cells can also activate memory T cells. The accumulated production of cytokines by
memory and naive T cells during a secondary infection along with complement activation
are thought to enhance the effect on vascular endothelial cells and lead to plasma leakage.
Figure reprinted from reference (68).
D. VIRUS STRUCTURE AND COMPOSITION
1. RNA
The viral family Flaviviridae is subdivided into the three genera - Flavivirus
Pestivirus and Repacivirus; a separate group of viruses that includes GB virus C/hepatitis
G viruses (GBV-C) also belongs to this viral family but has not been assigned a definite
taxonomic classification (69). Members of the genus Flavivirus have a type I cap
structure (m7GpppAmp) at the 5' end of the genome and a highly structured 3'
untranslated region (UTR) (70). The flavivirus genomic RNA also is distinguished by the
absence of a 3' -terminal poly(A) tract (71) There is evidence that the 5' and 3' ends
stack together to cause a cyclization of the genome which may be an important feature
for RNA replication in Flaviviruses (72 , 73). The hepaciviruses (hepatitis C virus;
RCV), pestiviruses and GBV-C control translation by an internal ribosomal entry site
(IRES) in the 5' UTR and have a shorter , less-structured 3' UTR than flaviviruses (74).
The four serotypes of dengue virus are members of the genus Flavivirus, which
also includes west nile , yellow fever and japanese encephalitis viruses (69). Flaviviruses
consist of a single stranded positive sense RNA genome that is approximately 11 kb. The
viral genome is translated in the cytoplasm as a polyprotein (Figure 1-4). The
translocation of the polyprotein back and forth across the endoplasmic reticulum (ER)
membrane is directed by signal and stop-transfer sequences (Figure 1-5). The polyprotein
is subsequently co- and post-translationally modified by viral and host-encoded proteases
to produc three structural and seven nonstructural proteins. The mature virion contains
the structural proteins: the capsid, C: a membrane associated protein (which is produced
from the precursor prM), M; and the envelope protein, E. The nonstructural (NS) proteins
include large, highly conserved proteins NS 1 , NS3 , and NS5 and four small hydrophobic
proteins NS2A , NS2B , NS4A , and NS4B (71 , 75 , 76).
2. Structural proteins
The C protein is highly basic and forms a structural component of the
nucleocapsid (76). The terminal hydrophobic signal sequence is cleaved by the viral
NS2B-NS3 protease before virion assembly resulting in the mature form of DENV C
protein (77, 78). The DENV C protein is necessary for encapsidation of the viral
genome , although the mechanism is not known. Infected cells release subviral particles
that do not contain either C or the viral genomic RNA , suggesting an important role for C
in proper packaging of the infectious virion (79). Recently, the structure of the DEN2V
C dimer was elucidated by nuclear magnetic resonation (NMR) techniques (80 , 81).
DEN2V C protein contains a hydrophobic cleft on one side where it is proposed to
interact with the viral lipid bilayer, and a positively charged region on the opposing side
that is thought to interact with the viral RNA (81).
The prM protein is a glycoprotein that forms heterodimers with E on the
intracellular immature virion surface. The dimerization of prM and E is thought to
prevent exposure of the fusion peptide within the cell (75). The prM protein contains a
stop transfer sequence and a signal sequence in two transmembrane helices. The stop
transfer sequence localizes both prM and E to the lumen of the ER (Figure 1-5). prM and
E dimerize within the lumen of the ER upon cleavage by a host signalase. Upon
maturation and release of the virion from the cell , prM is further cleaved by the host
enzyme , furin , to produce M. This process releases E from prM (82). The E proteins
then reorganize into homodimers (83 , 84). The mature virion has a smooth appearance
compared to the immature virion which contains spikes on the surface.
The structure of the E glycoprotein contains three domains. The amino terminus
is located in the center of the folded protein (domain I). Domain II contains the
dimerization domain and the fusion peptide. On the other side of domain I is domain III,
which contains the immunoglobulin - like domain. This domain is thought to bind to the
cellular receptor (reviewed in (85)).
Cells transfected with recombinant prM and E from tick borne encephalitis virus
(TBE) or DENV release viral-like particles that do not contain C or genomic RNA (86
87). The relationship between prM and E have been studied using viral like particles
which undergo the same maturation process as the intact virion (86).
3. Nonstructural Proteins
The seven nonstructural proteins , NS-l;NS2A, NS2B , NS3 , NS4A , NS4B , and
NS5 , are encoded in the 3' region of the viral genome (Figure 1- 4). The NSI protein
contains a signal sequence that is located in the carboxy terminus of the E protein and is
inserted into the ER (88). NSI is posttranslationally cleaved from NS2A by an unknown
ER-resident host proteinase (89). NSI is a glycoprotein that forms homodimers and
interacts with membranes (90-92). It can be secreted from infected cells or localize to
sites of RNA replication within the cell. Small amounts of the NSI protein associate with
the cell surface and are capable of signaling through a glycosyl-phosphatidylinositol
(GPI) anchor in response to cross-linking by NSI-specific antibodies (93-95). In addition
NS 1 is an essential component of the viral replicase (96 , 97).
The remaining nonstructural proteins are localized on the cytoplasmic side of the
ER membrane (89 , 98). The NS2A protein was found to be involved in proteolytic
cleavage of NS I at its carboxy terminus (88). The NS2B protein associates with NS3 to
form the viral protease. The NS2B-NS3 protease mediates cleavage of the viral
polyprotein at the NS2A/NS2B , NS2B/NS3 , NS3/NS4A, NS4A/NS4B and NS4B/NS5
junctions (99- 102).
The NS3 protein is part of the replicative complex and has several enzymatic
functions. The serine protease domain of NS3 is in the amino terminus of the protein (71
103- 105) whereas the carboxy terminus of the protein functions as a helicase (106, 107),
a nucleoside 5' -triphosphatase (NTPase) (107- 109) (104 D, and a RNA 5' -triphosphatase
(RTPase) (110). The small proteins NS4A and NS4B have not been studied extensively.
However, it has recently been shown that NS4B , and to a lesser extent, NS2A and NS4A
are able to block type I interferon (IFN) signaling (111). This effect is discussed further
below (SECTION I. FLA VIVIRUS EVASION OF THE IMMUNE SYSTEM).
The NS5 protein is the largest of the dengue proteins (104 kDa) and is highly
conserved among the flaviviruses (112). NS5 contains a well characterized RNA-
dependent RNA polymerase activity in the carboxy termnus (amino acids 455 - 900)
(113- 117). Amino acids 1 - 296 of the amino terminus of DEN2V NS5 exhibits
(nucleoside- O-)-methyltransferase activity on capped RNA (118). NS5 was found to
interact with NS3 to form a replication complex (119). In addition , NS5 can stimulate
the NTPase activity of NS3, which is necessary for unwinding of dsRNA substrates by
helicase activity during viral replication (120).
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Figure 1-4. Schematic of Oavivirus genome. U ntranslated regions of the genome (top),
with their 5' and 3' terminal structures , are indicated by black lines. The single open
reading frame encodes a polyprotein (middle) that is processed by the viral NS2B-NS3
protease and host proteases to the mature viral proteins (bottom). Cleavage sites for host
signalase (.), the viral serine protease (t), furin or other Golgi-Iocalized protease ("), or
unkown proteases (7) are indicated. Black bars represent hydrophobic regions. Shaded
regions indicate mature structural proteins. The genome is not drawn to scale. Figure
reprinted from reference (69) with permission from Lippincott Wiliams &Wilkins.
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Figure 1-5. Membrane topology of flavivirus proteins. The proposed orientation of the
flavivirus polyprotein cleavage products with respect to the ER membrane is shown. The
proteins are drawn to scale (areas are proportional to the number of amino acids) and
arranged in order (left to right) of their appe nce in the polyprotein. Mature structural
proteins are shaded and carboxy-terminal membrane-spanning segments of M and E are
indicated. Cleavage sites for host signalase (.), the viral serine protease (1), furin or other
Golgi-Iocalized protease ("), or unknown proteases (?) are indicated. Figure reprinted
from (69) with permssion from Lippincott Willams &Wilkins.
E. VIRAL LIFE CYCLE
Infection of the host cell with flaviviruses occurs by receptor-mediated
endocytosis into clarithin-coated pits (32 , 121- 124). Acidification of endosomes causes
E protein rearrangement to form homotrimers on the surface of the virion (83 , 84). It has
been proposed that flaviviruses follow class II membrane fusion (85). The E protein in
flaviviruses obtain their trimeric form after acidification and the fusion peptide is usually
internally located (125). The fusion peptide within domain II of flaviviruses are exposed
by receptor binding and low pH. The hinge between domains I and II presumably allow
E to insert the fusion peptide into the host's lipid bilayer. Domain III is thought to fold
back onto itself bringing the host bilayer and the viral bilayer into contact allowing
hemifusion. The E proteins then form trimers on the virion surface (85).
After the virion has fused with the host cell membrane , the nucleocapsid core is
released into the cytoplasm of the cell (Figure 1-6) (32 , 121 , 123, 126). The C protein
disassociates from the viral RNA and translation of the viral RNA is initiated. Following
translation and processing of the viral proteins , the non structural proteins form a viral
replicase and bind to the viral RNA , initiating replication of the viral genome (127).
Cytoplasmic membranes in the perinuclear region of the cell undergo proliferation
of the ER and subsequent appearance of smooth membrane vesicles during flavivirus
infection (93 , 94 128- 131). These vesicles are sites of viral RNA replication.
Once the viral proteins are translated and the genome is replicated , the virion
begins to assemble within the lumen of the ER. Immature viral particles are shuttled
through the trans-golgi network (TGN). The immature virion contains a spiked surface
which has been shown to be the prM protein capping the E protein (Figure 1-7) (75).
During exocytosis, furin protease cleaves prM to M releasing E (132). E then forms
homodimers on the surface of the virion. The mature viral particle has been shown 
cryoelectromicroscopy to have a spikeless , smooth surface with sets of three parallel
dimers containing E (Figure 1-7) (75 , 83). Mature viral particles are exocytosed via
secretory vesicles.
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Figure 1-6. Flavivirus life cycle. Virions enter the cell by receptor-mediated
endocytosis (1 2). Low pH of the endosomal vesicle initiates conformational changes in
the virion , fusion of the viral and cell membranes, and release of the nucleocapsid into
the cytoplasm of the cell (3 4). The positive-sense RNA is translated into a single
polyprotein that is co- and post-translationally modified by viral and host proteases (5).
Genome replication occurs on intracellular membranes in the perinuclear region (6).
Structural proteins and newly synthesized RNA bud into the lumen of the ER (7). Virus
assembly occurs on the surface of the ER. The resultant non-infectious , immature viral
'7'
and subviral particles are transported through the TGN (8). The immature virion particles
are cleaved by the host protease furin , resulting in mature , infectious particles. Mature
virions and subviral particles are released from the cell by exocytosis (9). Figure was
reprinted from reference (69) with permission from Lippincott Williams &Wilkins.
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Figure 1-7. Structure offlavivirus virions. The intracellular (immature) virion depicted
on the left shows the formation of prM and E heterodimers. Upon maturation, prM is
cleaved to form M (right side of virion), allowing E to form E homodimers. This results
in a smooth , spikeless surface. Figure reprinted from reference (69) with permission
from Lippincott Wiliams & Wilkins.
F. CELLS SUSCEPTIBLE TO DENGUE INFECTION
It is unclear which cells are primary targets of DENV infection in vivo. Initial
studies of tissue obtained at autopsy from DHF patients indicated that DENV was
associated with mononuclear cells such as Kupffer cells in the liver, pulmonary
macrophages , and mononuclear cells in the blood and skin (133). Additionally, DENV
has been isolated from peripheral blood leukocytes from patients with DHF (76, 134).
However, these cell types are not highly susceptible to DENV infection in vitro (135
136). Langerhans cells and monocyte-derived dendritic cells (DCs) have been shown to
be more permissive to in vitro DENV infection than monocytes (135). DENV-infected
DCs express maturation markers and produce TNFa and IFNa (137 , 138). In vitro, 
lymphocytes are also susceptible to DENV infection and produce TNFa and IFNa upon
infection , similar to monocytes (139).
DENV antigen has also been found in hepatocytes in tissue obtained from
autopsies of DHF patients (22 , 133 , 140). DENV infected patients were found to
have high AST levels, suggesting liver involvement (141- 143). These results correlate
with in vitro studies that show productive infection of five different liver cell lines and an
increase in AST and ALT levels (143). However, other immunological mechanisms can
induce liver damage such as activated T cells and cytokines (57 , 144)
In addition, DENV antigen has also been found in the sinusoidal endothelium
from autopsies of DHF patients (22 , 23 , 133 , 140). In vitro DENV can also productively
infect endothelial cells (145 , 146). Other cell types such as T cell lines , monocytic cell
lines and skin fibroblasts can be infected by DENV in vitro (147- 149).
G. RECEPTOR FOR DENGUE INFECTION
The receptor for dengue viral infection is still undefined. Studies have shown that
recombinant E protein binds to the highly sulfated form of the glycosaminoglycan (GAG)
heparin sulfate (HS) (150, 151). Treatment of cells with heparin , heparin-derived
oligosaccharides , or suramin, a polyionic sulfate , inhibited dengue virus envelope protein
binding to Vero cells and viral infectivity in vitro. HS is involved in many biological
roles including cell attachment and migration, cell signaling, and virus infection (152).
HS is ubiquitously expressed on the surface of many cell types and is used by several
microorganisms , including viruses , gram-positive and gram-negative bacteria, and
parasites to gain entry into host cells (153- 155). Viruses that use HS GAGs include
Sindbis virus (156 , 157), Venezuelan equine encephalitis virus (158), Ross River virus
(159) and human immunodefiency virus (160).
It has been proposed that a coreceptor is involved for DENV infection to explain
the limited cell tropism of DENV (161 , 162):- Potential receptors/coreceptors include a
45 kDa gy1coprotein in C6/36 cells (163), a 74-kDa protein present in Vero cells (162),
two proteins of approximately 40 to 45 kDa and 70 to 75 kDa from a B-cellline and a
myelomonocytic cell line (164), a 105 kDa protein in erythroleukemia cells (165),
membrane proteins of 27 67, and 87 kDa in monocytes/macrophages (166) and
proteins of 29 and 43 kDa from an endothelial cell line (145). However, these proteins
have not been definitively identified.
Recently, Reyes-del Valle et al used a His-tagged E protein of DENV as bait to
pull down and analyze cellular proteins from neuroblastoma cells and U937 , a
myelomonocytic cell line , using affinity chromatography (161). They found an 84 kDa
molecule that interacted with E and identified it as heat shock protein 90 (Hsp90) by
mass spectrometry. Antibody to Hsp90 inhibited DEN V infection of
monocyte/macrophage cells , supporting its potential role as a cellular receptor for DENV.
DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN , CD209), a dendritic cell
type lectin and its homologue L-SIGN have been shown to mediate DENV infection of
primary dendritic cells or cells transfected with DC-SIGN or L-SIGN (167 , 168).
Antibodies directed to DC-SIGN inhibited infection of DCs. Lozach et al found that
interaction of E protein with DC-SIGN mediated DENV infection of monocytic-derived
DCs but not Langerhans cells (169). Furthermore , endocytosis through the interaction
with DC-SIGN was not required for viral replication in HeLa cells , suggesting that DC-
SIGN functions as an attachment receptor for enhanced infection through an unidentified
receptor.
H. INNATE IMMUNITY
1. Viral induction of Type I IFN
The innate immune system is the first line of defense against an invading viral
pathogen. Once the host recognizes the invading virus , signaling pathways are activated
to induce expression of multiple transcription factors that bind to the interferon a and 
promoters (170- 172). The transcription factors that bind to the IFN promoter positive
regulatory domain I (PRDI), PRDII and PRDIV are interferon regulatory factor (IRF-)3
and IRF- , NFKB , and ATF-2/c-Jun , respectively. NFKB activation occurs by virus-
induced phosphorylation and degradation of the IKB protein (173). Activating
transcription factor-2 (ATF-2) is also activated by phosphorylation through MAP kinase
activation (170).
The RNA helicase , RIG- , senses dsRNA in the cytoplasm of the infected cell
through pattern recognition receptors (PRR) (174). Toll receptor 7 (TLR7) and TLR8
recognize single stranded RNA (ssRNA) in the endosomes (175- 177) whereas TLR3 and
TLR9 recognize double stranded RNA (dsRNA) and unmethylated DNA, respectively
(178 , 179). Activation of RIG-I and TLRs activates two IKB kinase (IKK)-related
kinases , IKKE and TANK-binding kinase -I (TBK- l) (180 181) These kinases
phosphorylate and activate interferon regulatory factor 3 (IRF-3), which leads to IFN
induction.
IRF-7 expression is induced by type I IFN and then activated by viral replication
(182- 184). IRF-7 is also involved in promoting IFN gene expression to elicit a full IFN
response (172 , 185- 187).
2. Signaling from Type I IFN receptors
The receptor for IFNa and is composed of two proteins , IFNAR- l and IFNAR-
2 (188). Upon IFN binding to its receptor, the Janus tyrosine kinases (1ak) nonreceptor
tyrosine kinases, Tyk2 and Jakl , which are constitutively bound to the subunits of the
IFN receptor, are phosphorylated (Figure 1-8). Phosphorylation of Tyk2 and Jaklleads
to phosphorylation of tyrosine residues within the cytoplasmic tail of the receptor and
recruitment of signal transducers and activators of transcription (Stat) proteins (189).
The phosphorylated Janus kinases (Jaks) phosphorylate the receptor bound Stat proteins.
The phosphorylated Stats form homo- and heterodimers that can translocate into the
nucleus and bind in conjunction with a DNA binding adapter protein of the IFN
regulatory factor (IRF) family (ISGF3) to DNA elements within IFN-sensitive genes
(ISG) such as IFN-stimulated response elements (ISREs) (190). Genes that contain ISREs
which include double-stranded RNA activated protein kinase (PKR), 2' ,5' -oligoadenylate
synthetase (GAS), myxovirus induced protein A (MxA), guanylate-binding protein
(GBP), IRF7 , chemokines and cytokines are activated by the JakfStat pathway (173). In
addition , Stat homo- and heterodimers can bind to gamma activated sequences (GAS)
within promoters of other ISGs such as c-fos and IRF- 1 (191). Activation of the p38
MAPK pathway is important for full IFN-induced transcriptional activation through ISRE
and GAS elements (192 , 193).
3. DEN V infection and innate immunity
As with other viruses, the innate immune response is activated by DENV
infection and can inhibit DENV replication. Knockout mice that lack IFNa/ and IFNy
receptors develop limb paralysis and die after challenge with del)gue virus (194, 195).
Pretreatment of cultured cells with IFNa/ dramatically reduced DENV replication
through inhibition of translation of DENV RNA (196 , 197). In contrast, addition of
IFNa/ after DENV replication has little effect on DENV replication (196, 197). These
data suggest that IFN signaling is not able to properly function in cells that are infected
with DENV. In addition , DENV replicates to high titers (10 infectious doses per ml) in
humans even though there are high levels of circulating IFNa (198-200). These results
suggest that there are mechanisms that DENV uses to counter the IFN response , as seen
with other viruses (201 202).
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Figure 1- 8. Cellular response to viral infections. Viral dsRNA activates the
transcription factors NFKB , AP- , and IRF-3. Full activation of the IFN promoter
requires cooperative action of these transcription factors , but, IRF3 is most important.
Phosphorylation and activation of IRF-7 induces the expression of several IFNa subtypes
which amplify the IFN response. Activation of both RIG- , a dsRNA sensor , and toll
receptors (TLRs) activates the kinases IKKe and TBK- l. These kinases phosphorylate
and activate IRF-3 leading to IFN induction. IFNa/ can then bind to its receptor
(IFNAR) and activates the expression of numerous ISGs through activation of the
Jak/Stat pathway. Mx , GAS and PKR are enzymes with antiviral properties. Figure
reprinted from reference (203).
I. FLA VIVIRUS EVASION OF THE IMMUNE SYSTEM
DNA viruses have evolved to acquire host genes and use these genes as decoys to
evade the humoral or cellular antiviral response (204-206). RNA viral proteins , on the
other hand, tend to be multifunctional due to size constraints of the viral genome.
Therefore , RNA viruses tend to use alternate mechanisms for immune evasion.
One mechanism that RNA viruses use to evade the immune system is to generate
quasispecies due to replication with a low fidelity RNA polymerase (207 208). These
viruses with random mutations in their genome can evade recognition by neutralizing
antibodies and T cells. Changes in the hypervariable region of the immunodominant E2
protein in HCV , for example , have been associated with viral persistence and loss of
humoral response (209-212). In addition , the loss of antigen presentation and capacity to
stimulate T cells to proliferate and produce cytokines in HCV correlates with changes in
the immunodominant epitopes of NS3 protein-(213-215). Quasispecies of DENV with
changes in C , E and NS2B proteins have been identified but have yet to be correlated
with disease severity (216 217).
The initial immune response to viral infection is IFN production (218). Evidence
has shown that flaviviruses are able to attenuate IFN antiviral effects (9 , 196). The
distantly related member of the family Flaviviridae, HCV , has evolved multiple
mechanisms to inhibit IFN antiviral activity. Expression of HCV proteins blocks the
transcriptional response to IFNa (219). HCV NS5A and E2 proteins prevent
phosphorylation of eIF2a and the arest of viral translation by inhibiting PKR activity
(220-224). In addition, the HCV core protein expressed in HepG2 and Huh-7 cells
inhibited IFNa-induced nuclear STATI import (225). This led to reduced MxA
expression and increase expression of suppressor of cytokine signaling-3 (SOCS3) and
thereby preventing the activation of ISGs in response to IFN (225 , 226).
RIG-I has recently been identified as a cytoplasmic dsRNA sensing mechanism
and induces IFN expression. The RIG-I pathway elicits the activation of transcription
factors such as NFKB and IRF- , which are also involved in chemokine transcription
(174). The HCY NS3/4A protease inhibited IRF-3 phosphorylation by inhibiting RIG-
dependent signaling to the IFN pathway (227 , 228). In addition, Otsuka et al
demonstrated that NS3 directly interacts with TBKI. This interaction prevents TBK1
from associating with IRF- , thereby inhibiting activation ofIRF-3 (229).
DENY has also been shown to counter the antiviral effects of IFNa. Diamond et
al found that treatment of HepG2 , Huh-7 or K562 cells with IFN as little as four hours
after infection with DENY resulted in almost a complete loss of antiviral effect (196).
Munoz-Jordan et al reported that the DENVNS4B protein could block the IFN-induced
signal transduction cascade by interfering with Statl function (111). NS4A and NS2A
proteins were also able to block IFN signaling but to a lesser extent. NS4B , NS2A and
NS4A together were able to block IFN signaling completely. Recently, Jones et al used
K562 cells stably transfected with a dengue replicon and found that Statl
phosphorylation was inhibited during IFNa signaling but not during IFNy signaling
(230). In addition , they report that DENY infection of K562 cells and cells containing
the DENY replicon had reduced levels of phosphorylated Stat2, which is specific to the
IFNa pathway. These results suggest that DENY specifically inhibits the IFNa pathway
through the inhibition of Stat2. The evolution of independent mechanisms to inhibit the
antiviral activity of IFN by many viruses highlights its key role as one of the first
antiviral defense mechanisms (218).
J. CHEMOKINES
Chemokines have been implicated in many aspects of immunity including
hemopoietic cell migration, Thl/Th2 development , angiogenesis/angiostasis , cell
recruitment, lymphoid trafficking and lymphoid organ development (231). Chemokines
are small molecules whose primary role in immunity is to attract leukocytes to sites of
inflammation. Chemokines can be divided into four classes - CC- , CXC- , C- , CX
chemokines. These four classes were based on the number and spacing of conserved
cysteine residues found in the N-terminus of the polypeptide (232). Cells attracted to
chemokines express heterotrimeric , 7 -transmembrane-spanning, G-protein coupled
receptors (232). Chemokine receptors have a short extracellular N-terminus that is
essential for receptor activation and a short intracellular C-terminus (233). Differential
expression of chemokine receptors and the expression of specific chemokines from
leukocytes determine the migration of particular-cells during inflammation (204).
Chemotaxis of cells toward a chemokine gradient requires signaling from the
short intracytoplasmic tails of the G-protein coupled receptors (234 , 235) . After ligand
binding, the receptor-bound heterotrimeric G ya subunits dissociate into Gai and G
subunits. G y can directly activate phosphoinositol 3 kinase (PI3Ky) and phospholipase
C (PLC) (234 235). PLC yields inositol (1,4,5) triphosphate and diacylglycerol (DAG)
(236). Inositol triphosphate mobilizes the release of intracellular stores of calcium
which , in combination with DAG, activates many protein kinase C isoforms (237).
PI3Ky activation is important for cytoskeletal rearrangement, chemotaxis and
degranulation (238). The Gai subunit can induce Src family activation and the p85/p11O
PI3K pathway, which are also involved in cell polarization/movement and the
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degranulation response (232).
Chemokines regulate the migration of leukocytes into extravascular tissues (233
239). Leukocytes stop active rollng along the endothelium at sites of infection once
specific vascular ligands of the immunoglobin family, such as E- selectin, intercellular
adhesion molecule (ICAM), vascular cell adhesion molecule I (VCAM-l), and mucosal
addressin cell adhesion molecules 1 (MAdCAM - I), bind to their leukocyte integrin
receptors (239 240). Chemokines expressed at the sites of infection produce a gradient
of proteins. These chemokines increase the avidity of leukocyte receptor binding to
endothelialligands , thus creating a tight adhesion of the leukocyte to the vascular
endothelium. This adhesion allows the leukocyte to transmigrate or undergo diapedesis
at intercellular borders or junctions of endothelium (239 , 241). Leukocytes then move
along the chemokine concentration gradient toward the site of infection.
Chemokines and chemokine receptors are important for defense against viruses
(242). Efficient migration of activated leukocytes to the sites of infection influences the
outcome of disease. However, viruses can utilize the chemokine system to counteract the
immune system. Examples include the use chemokine receptors CCR5 and CXCR4 for
HIV infection of T lymphocytes and the expression of the respiratory syncytial viral
glycoprotein , G , which can bind the fractalkine receptor, CX CRI and inhibit chemotaxis
of natural killer cells and Thl cells (243).
IL-
lnterleukin (IL)-8 (also known as CXCL8) is a member of the CXC chemokine
family and interacts with two receptors , CXCRI and CXCR2 (244). IL-8 is produced by
many cell types , including monocytes/macrophages , T cells , neutrophils , fibroblasts
endothelial cells , keratinocytes, hepatocytes , astrocytes and chondrocytes. Moreover, IL-
8 has chemoattractant effects on neutrophils and T cells (245 246). Expression of IL-8 is
induced by a variety of stimuli such as LPS , TNF, IL- 1 and viral infection (244). IL-
has been shown to promote adhesion of neutrophils to endothelial monolayers (247) and
stimulate neutrophil migration across endothelium (248), pulmonary epithelium (249)
and fibroblast monolayers (250).
The core IL-8 promoter contains AP- , NFKB and CAAT/enhancer binding
protein (c/EBP) binding sites (Figure 1-9) (251). In unstimulated cells, the IL-8 promoter
is repressed by three mechanisms. NFKB-repressing factor (NRF) is bound to the
negative regulatory element (NRE), which overlaps the NF1d binding site (252).
Octamer- l (Oct- I) is bound to an octamer binding site that is on the complementary
strand in the opposite direction of the c/EBP binding site (253). Lastly, histone proteins
are deacetylated by the action of histone deacetylase 1 (HDAC- l) (254).
Upon activation of the IL-8 promoter, the CREB-binding protein (CBP)/p300
hyperacetylates histones which results in chromatin remodeling (255). In addition
c/EBP replaces OCT - 1 and the p65 subunit of NFKB binds to its cognate site next to
NRF. NRF then becomes a coactivator (252). In addition , AP- l and NF1d become
phosphorylated (251). Studies have shown that c/EBP binds weakly to the IL-8 promoter
site and that strong cooperative binding occurs when NFKB is bound to its adjacent
binding site (256).
Another level of control of IL-8 expression is post- transcriptional regulation by
the p38 mitogen activated protein kinase (MAPK) pathway (251). Activation of the
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MAPK kinase 6 (MKK6) and MAPK-activated protein kinase-2 (MK-2), which are
components of the p38 MAPK pathway, was shown to induce stabilization of the IL-
transcript (257-259). In addition, AP- l is activated by MAPKs. There are three MAPK
pathways that can activate AP- l and contribute to IL-8 gene expression - the
extracellular-regulated protein kinase (ERK), JUN- terminal protein kinase (JNK), and
p38 MAPK cascades (251 260).
2. RANTES
RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted),
also known as CCL5 , is a member of the CC family of chemokines. RANTES can bind
to four receptors; CCRl , CCR3 , CCR4 , and CCR5 (261-264). RANTES can attract
many cell types , including CD4+ and CD8+ naIve and memory T cells, NK cells , dendritic
cells and monocytes (265-269).
RANTES is induced in a variety of tissues in response to tissue damage, infection
or foreign substances (270-272). The promoter for RANTES has been characterized in T
cells, monocytes , astrocytes and mesangial cells (272-275). Six regions of the RANTES
promoter, R(A-G), have been identified as important for RANTES expression, but these
regions are not all functional in every cell type (Figure 1-9). For instance , in T cells the
binding sites for R( C)Flat, (RANTES factor of late activated T lymphocytes) (RFLA T)-
c/EBP and NFKB are important for RANTES transcription whereas Ets , CREB , AP-
c/EBP, SP- l and NFKB binding sites are important in monocytes (272). In addition , three
ISRE sites have been located between R(D) and R(E). The ISRE sites are important for
binding of IRF- , which is essential for virus- or IFN-stimulated RANTES expression
(276).
3. MIP- la and MIP-
The macrophage inflammatory protein- l (MIP- I) family consists of proteins that
are secreted by activated T cells , B cells , monocytes , mast cells , neutrophils, Langerhans
cells , astrocytes , endothelial cells, fibroblasts and smooth muscle cells in response to
many stimuli including LPS , viral infection TNFa and IL- Ia/ (277-281). MIP-
proteins are small (8-10 kDa) chemokines of the CC subfamily and are involved in
recruiting proinflammatory cells to the site of injury or infection (282). MIP- l proteins
are important chemoattractants of T cells (283), B cells (284), monocytes (285), NK cells
(286), basophils (287) and eosinophils (288). Two members of the MIP- I family, MIP-
la (CCL3) and MIP- (CCL4), have been characterized and bind to the G-protein
receptors , CCRI and CCR5 (282).
The promoter for MIP- I has not been well characterized but there is evidence that
NFKB , AP- l and c/EBP playa role in transcnption (Figure 1-9) (289-291).
4. IPIO
Inteferon-gamma inducible protein 10 (IPI0/CXCLI0) is part of the CXC
subfamily of chemokines and was first identified as an IFNy inducible gene (292). It is
expressed by a variety of cells in response to IFNy, viral infection and LPS including
endothelial cells (293), macrophages (294) and astrocytes (295). The receptor for IPlO is
CXCR3 , which also binds the chemokine Mig (monokine induced by IFN-y) (292). IPI0
chemoattracts monocytes , T lymphocytes , and natural killer (NK) cells (286 , 296). In
addition, IPI0 can regulate maturation of T-cell and bone marrow progenitors , modulate
adhesion molecule expression , and inhibit angiogenesis (297).
The IP 10 promoter contains binding sites for lSRE binding proteins , GAS , NFKB
and AP- I (Figure 1-9). The NFKB and ISRE sites have been shown to be most important
for full IP 10 expression (298).
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Figure 1-9. Schematic of chemokine promoters. Transcription factor binding sites for
IL-8 (251), RANTES (272), IPlO (298) and -MIP- la (290) promoters. Note: not to scale.
K. TRANSCRIPTION FACTORS INVOLVED IN CHEMOKINE GENE
EXPRESSION
1. AP-
The transcription factor AP- l contains variable combinations of basic-region
leucine zipper (bZIP) domain proteins from Jun (c-Jun , JunB and JunD) and Fos (c-Fos
FosB , Fra- l and Fra-2) families, resulting in Jun homodimers and Jun-Fos heterodimers
(299-302). Jun-Jun and Jun-Fos dimers bind with highest affinity to the 12-
tetradecanoylphorbol- 13-acetate (TPA) response element (TRE) (TGA(C/G)TCA) (303).
Phosphorylation of c-Jun by c-Jun N-terminal kinase (JNK), a member of the MAPK,
mcreases the transcriptional activity of AP- l. In response to various stimuli , the JNKs
are activated by phosphorylation of specific serine and threonines by MKK 4 or 7, which
are in turn activated by phosphorylatio by MKKK (Figure 1- 10) (304). ERKI and ERK2
can also contribute to the induction of AP- l by phosphorylating proteins that increase c-
Fos synthesis (305). The p38 MAPK pathway has been shown to increase the half-life of
cytokine and chemokine mRNA through the AU-rich elements and thereby enhance the
effects of AP- l induction of pro inflammatory genes (304).
Jun and Fos proteins can also interact to form heterodimers with other bZIP
proteins from subfamilies ATF , MAF, CNC and c/EBP allowing them to target DNA
binding sites such as the cAMP response element (CRE), the antioxidant response
elements (ARE), and half-sites composed of half of a TRE site and half of a MAF- or
CNC-binding site (306). AP- l proteins can also interact with other proteins including
NF-KB CBP (CRE-binding-protein-binding protein) (p300), SMAD-3 and - , and the
retinoblastoma protein (306). Specifically, the basic leucine zipper (bZIP) regions of c-
1';
Fos and c-lun have been shown to interact with the ReI homology domain in the p65
subunit of NFKB (307). Unlike the interaction between NFKB and c/EBP, there is
enhanced DNA binding of NFKB and lun or Fos complexes to both the NFKB site and
the AP- l site (307 , 308).
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Figure 1-10. AP- l activation pathway. Cytokines activate AP- l through a cascade
involving JNK phosphorylation and activation by MAP kinase kinase 4 or 7
, and
subsequent c-Jun phosphorylation. The ERKI/2 pathway is also activated and induces the
synthesis and phosphorylation of c-Fos. c-Jun then dimerizes with c-Fos and binds to the
AP- l site in inflammatory gene promoters. In addition to JNK and ERK1I2
, which
regulate the activation of the AP- l complex , the p38 MAPK pathway has been found to
both stabilize proinflammatory gene mRNAs (such as cyc100xygenase (COX)-
, TNF-a
IL- , and IL-8) and inhibit innate immune response genes (such as TLR2). Figure
modified from reference (304) with permission.
2. c/EBP
CCAAT/enhancer binding protein (clEBP , also known as NF-IL-6) was originally
identified as a DNA-binding protein responsible for IL- 1-stimulated IL-6 induction and
includes c/EBPa, clEBP , c/EBPO, c/EBPc , c/EBPyand c/EBP (309 , 310). c/EBPB is
expressed in various tissues such as the liver, adipose tissue , intestine , ovary, lung, skin,
brain, kidney, heart, hematopoietic tissue , spleen , and mammary gland (310). Many of
the isoforms of c/EBP are expressed in liver and adipose tissues and regulate several
hepatocyte- and adipocyte-specific genes (311).
The c/EBPs are a family of bZIP transcription factors that contain a leucine zipper
motif involved in dimerization and an adjacent basic region involved in DNA binding in
the carboxy termnus (310). The amino terminus contains a transactivation domain. The
c/EBP protein is normally repressed and is activated by phosphorylation of threonine
residues by many kinases including the Ras activated MAPK pathway, PKA , and PKC
(Figure 1-11). Upon activation , c/EBPs can bind consensus palindromic DNA binding
sites ( a/gTTGCGc/tAAc/t) as homodimers or heterodimers with other c/EBP family
members (312).
In addition , c/EBP proteins can heterodimerize with other bZIP family members
such as ATF (313 , 314), CREB (315), and AP- l family members Fos and lun (316). The
members of the NFlCB family, p65, p50 and ReI are also able to interact with c/EBPa,
c/EBP and c/EBO to stimulate promoters with c/EBP binding sites but at the same time
to inhibit promoters with NF1d sites (256). Studies have also shown a direct interaction
between the bZIP region of c/EBP and the ReI homology domain of NF1d (256).
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Figure 1-11. clEBP activation pathway. The c/EBP transcription factor is activated by
phosphorylation by the p38 MAPK pathway in response to stimuli such as cytokines and
LPS. c/EBP binds to the C/CAA T consensus site in various promoters including iNOS
IL-8 and RANTES. Figure modified from reference (317).
3. NFKB
NFKB is an activator of a broad class of immune system genes including
cytokines , immunoreceptors , antigen presentation proteins , regulators of apoptosis , and
growth factors (318). NFKB is present in virtually all cell types and was first described
as a nuclear factor necessary for immunoglobulin kappa light chain transcription in B
cells (319). The NFKB family is composed of five structurally related DNA binding
proteins; NFKBl/p50 NFKB2/p52 , RelA/p65 RelIc-ReI , and RelB (320). All NFKB
subunits contain a highly homologous ReI homology region located in the amino-
terminus that mediates protein-DNA interactions. NFKB subunits also contain a
dimerization domain located in the carboxy-terminus (321). Although the most common
NFKB complex is a heterodimer consisting of RelA/p65 and p50 subunits, various
combinations of heterodimers and homodimers can occur (320). ReIA, Rei and RelB
contain a transactivation domain in the carboxy-terminus whereas p50 and p52 lack a
transactivating domain (322 , 323). Therefore , heterodimer combinations of NFKB
proteins are transcriptionally active , whereas p50 homodimers and p52 homodimers are
thought to be repressive (320).
NFKB activation is tightly regulated. Inactive NFKB is sequestered in the cytosol
by IKB inhibitory subunits (324, 325). Following stimulation, phosphorylation of two
tandem serine residues on the N-termnal domain of the IKB molecule occurs by
activation of two IKB-specific kinases , IKKl/a and IKK2/ (Figure 1- 12) (324). IKB is
then ubiqllinated and degraded by the proteasome, allowing nuclear translocation of
NFKB. NFKB activity is further regulated by post translational modification such as
phosphorylation and acetylation (326).
NFKB has been found to interact with other transcription factor families
including AP- l (307) and clEBP (308) as described above.
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Figure 1- 12. NFKB activation pathway. Cytokine stimulation of cells activates IKK
which phosphorylates IKB. Phosphorylated IKB becomes ubiquitinated and is then
degraded by the proteasome. NFKB , as depicted by p65/p50 heterodimer, translocates to
the nucleus and activates transcription of inflammatory genes. Figure modified from
reference (304) with permssion.
L. PHARMACOLOGICAL INHIBITORS OF CYTOKINE AND CHEMOKINE
PRODUCTION
Due to the important role of cytokines in inflammatory diseases, substantial
efforts have been made to identify pharmacologic inhibitors of cytokine production.
Pharmacological agents are commonly used to help define signaling pathways induced by
various stimuli. Pharmacological inhibition of inflammatory gene expression is
accomplished through various mechanisms including transcriptional control, particularly
ofNFKB and AP- , as well as posttranscriptional and translational control (327-329).
These small molecule inhibitors can access signaling pathways within a cell and can have
wide ranging anti-inflammatory theurapeutic potential through inhibition of
cytokines/ chemokines (330).
1. SB203580
SB203580 is a pyridinyl imidazole compound that has been shown to inhibit p38
MAPK activation through competitive binding in the ATP pocket ofp38 MAPK (331).
The p38 MAPK pathway consists ofMAPK kinases (MKK)-3 and 6, p38 and
downstream MAPK-activated protein kinases (MAPKAPK)-
, -
3, and - , MAPK-
interacting kinases (Mnk)- 1 and - , and mitogen- and stress-activated protein kinases
(Msk)- 1 and -2 (332). It has been shown that p38 MAPK can stabilize mRNAs
including COX-2 (333), IL- (334), Oro-a (334), IL-6 (335), TNF-a (336), MIP-
(336), and granulocyte/macrophage colony stimulating factor (OMCSF) (337). It is been
suggested that p38 MAPK stabilization occurs through AU-rich elements in the mRNA
(338). AU-rich elements destabilize mRNA by targeting it for deadenylation (258).
Although the precise mechanism is unknown, activation of p38 MAPK can inhibit this
process and stabilize the mRN A.
There is evidence that MAPKs such as p38 can contribute to NFKB activation
after binding to DNA elements, by facilitation. of p65 subunit phosphorylation or
interaction with the co-activator proteins CBP/p300 (339 , 340). Another study found that
inhibition of p38 MAPK by SB203580 or another p38 MAPK inhibitor, SB202190
blocked IL-8 transcription and cytokine release in human bronchial epithelial (BEAS-2B)
cells infected with Streptococcus pneumoniae (341) The level of IL-8 promoter-bound
p65-containing NF1d dimers was not inhibited with p38 MAPK inhibitors. However
phosphorylation on serine 536 of p65 that was bound to the IL-8 promoter was
significantly reduced in these cells. In addition, RNA polymerase II recruitment , which is
a measure of overall promoter activity, was also blocked. Recently, it was also shown
that SB203580 could significantly suppress the release of IL- , MIP- , IL-8 and MCP-
in eosinophils stimulated with the Th2 cytokine IL-25 (342). These studies suggest that
SB203580 can inhibit cytokine/chemokine expression through inhibition of NFKB
activation.
Inhibition of p38 MAPK can also have detrimental effects in inflammatory
diseases. Tristetraproline (TTP), which is involved in regulating stability of TNFa and
GM-CSF mRNAs , requires p38 MAPK for expression (343-345). TTP deficient mice
show an inflammatory phenotype due to high levels of TNFa protein and mRNA (346).
In addition, IL- , which has the ability to down-regulate inflammatory responses (347),
is suppressed by inhibition ofp38 MAPK using SB203580 or SB202190 in LPS-
stimulated monocytes (348 349).
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2. Rolipram
Rolipram ((:!)-4-(3' -cyclopentyloxy-4' -methoxyphenyl)- pyrrolidone)) is a
selective inhibitor of phosphodiesterase (PDE) IV. PDE IV is the predominant
isoenzyme expressed in myeloid and lymphoid cells (350). Inhibition of PDE IV leads to
an increase in the intracellular concentration of cAMP (351). cAMP is the product of
synthesis by adenyl cyclases and degradation by other phosphodiesterases (PDEs) (352).
cAMP binds to and activates protein kinase A (PKA), which allows phosphorylation of
transcription factors that bind to the cAMP response elements (CRE) or CRE binding
proteins (CREBs) (353).
Rolipram has been used in clinical trials safely as an antidepressant (354, 355).
Rolipram has also been shown to suppress activation of inflammatory cells (356).
Production of TNFa was suppressed in LPS stimulated monocytes with treatment of
rolipram (357). It has also been shown that rollpram can significantly decrease IL-8 and
TNFa production and migration of eosinophils and neutrophils into bronchoalveolar
lavage fluid in experimental antigen-induced asthma in monkeys (358). Another study
analyzing the effect of rolipram on HIV infected primary T cells showed that rolipram
reduced the production of TNFa and IL- I0 through day 9 post infection (359). Jimenez
et al reported that rolipram reduced the production of TNFa, IL- , IL- , and IL-2 by
activated human T cells (350). Moreover, rolipram and pentoxifylline (a nonspecific
phosphodiesterase inhibitor) inhibited the activation of NFKB and NF A T and stimulated
the activation of AP- 1 and CREBs (350 359).
3. Dexamethasone
Dexamethasone is a glucocorticoid that has been shown to playa role in
suppressing inflammation. Glucocorticoids bind to a glucocorticoid receptor (GR) that is
generally localized in the cytoplasm of many cell types (360). Upon binding, the GR
moves into the nucleus and binds as a homodimer to DNA at glucocorticoid response
elements (GREs). Binding of GREs can lead to induction of expression of
glucocorticoid-responsive genes such as the anti-inflammatory proteins IL- l receptor
antagonist, serum leukoproteinase inhibitor, clara cell protein 10 (CCI0) and lipocortin-
(361). An increase in IKBa expression has also been shown to occur in lymphocytes in
response to glucocortocoid treatment, thereby inhibiting NFKB (362).
Increased gene transcription occurs due to local unwinding of the DNA (363). IL-
induces chromatin remodeling, allowing p65 to bind to DNA , causing histone
acetylation of CBP and the formation of a CBP-associated HAT complex (364). In
contrast, dexamethasone has been shown to inhibit IL- induced gene expression (360
365). The mechanism of GR inhibition of gene transcription occurs by disrupting the
CBP-associated HAT activity and recruiting HDAC to the p65/CBP complex, which
further inhibits HAT activity and increases nucleosome compaction. This leads to
repression of transcription.
Glucocorticoids are most noted for their ability to inhibit expression of
inflammatory genes such as IL- , IL- , IL- , IL- , IL- , IL- , IL- , IL- , TNF-
GM-CSF and the chemokines IL- , RANTES , Eotaxin, MIPla, MCP- l and MCP-
(reviewed in (366J). The inhibitory effect of glucocorticoids is mediated by the
interaction between nuclear GR and transcription factors involved in expression of
inflammatory genes including AP- , NFKB and c/EBP (reviewed in (367J).
Dexamethasone treatment in the presence of cotransfected GR inhibited activation of
NFKB and AP- l reporters (368). The zinc finger domain of GR was found to be
necessary for the inhibition of p65 subunit of NFKB and AP- l. However, dexamethasone
treatment of cells transfected with fos , jun and NFKB expression plasmids did not inhibit
transcription from the NFKB reporter construct. They conclude that synergistic
NFKB/ AP- l activity was unaffected by dexamethasone.
Overall, studies indicate that dexamethasone treatment can inhibit NFKB
activation through many mechanisms including synthesis of IkBa, nucleosome
compaction or interaction of the p65 subunit of NFKB with the GR.
4. Indomethacin
Membrane phospholipids are converted into arachidonic acid by phospholipase
. Arachidonic acid is then converted into prostaglandin (PG) H by COX , and then to
prostanoids by specific synthases (369). There are three COX isoforms; COX-
constitutively produces housekeeping prostanoids, COX-2 is induced by inflammatory
cytokines and COX-3 is a splice varant of COX- l (369, 370).
Indomethacin is a nonselective COX inhibitor that has been shown to inhibit IL-
secretion in airway smooth muscle cells stimulated with bradykinin (371), increase IL-
in monocytes (372) and increase TNFa production in LPS stimulated monocytes and
macrophages (373 , 374). Previous research analyzing the effects of multiple NSAIDs
indicates that the anti-inflammatory effects of indomethacin do not occur through the
inhibition of NFKB (375-377), AP- l (378 , 379) or p42/p44 MAPK (380).
5. PDTC
PDTC is a derivative of DDTC (diethyldithiocarbamate , DDTC). DDTC has
been used for the treatment of metal poisoning in humans (381) In addition , DDTC has
been used in patients enrolled in clinical human immunodeficiency virus (HlY) studies.
Treatment of HIY -infected individuals with DDTC was associated with a delay in the
onset of acquired immune deficiency syndrome (AIDS) (381-383). This effect is thought
to be due to inhibition of NFKB activation (382, 384 , 385). PDTC has also been shown
to inhibit NFKB and has advantages over DDTC in that it can traverse the cell membrane
and has prolonged stability at physiological pH (385 , 386).
PDTC is an antioxidant that inhibits reactive oxidative species (ROS) (386 387),
inducible nitric oxide synthase (iNOS) activity and nitric oxide production (388). Studies
have shown that PDTC can inhibit induction of chemokines such as IL-8 from cells
including human dermal microvascular endothelial cells in vitro (389), epithelial cells
(390) eosinophils (391), human PBMC (392fand a lung cancer cell line (393) in parallel
to its inhibition of NFKB.
M. DENV INFECTION AND CHEMOKINES
The pathogenesis of dengue disease is not completely understood but thought to
be due to dysregulation of the immune response. Chemokines have been proposed to
contribute to inflammation and disease pathogenesis by attracting memory T cells to the
sites of viral replication during a secondary DENV infection (68). DENV-specific
memory T cells have a rapid response to DENV antigen and can increase the
inflammatory response and plasma leakage during DENY infection.
In this regard , studies of chemokine induction by DENV have been done in
various cells. Enhanced levels of chemokines such as MIP- , MIP- , IL-8 and
RANTES has been reported in PBMC , blood, serum and pleural fluids from DENY
infected patients (394-397). Spain-Santana et al detected an increase in the expression of
MIP- la and MIP- mRNA in PBMC of dengue patients during acute ilness (396). Lin
et al reported increased RANTES levels in plasma samples of DENY -infected patients
when compared to patients with other febrile ilnesses (397). Raghupathy et al reported
that levels of IL-8 protein in blood or pleural fluid were elevated in patients with DHF.
In addition, they found higher levels of IL-8 mRNA by quantitative real time polymerase
chain reaction (RT-PCR) in patients with severe disease when compared to DF patients
(394). Juffries et al assessed the levels of IL-8 in plasma samples from DENY infected
children in relation to levels of neutrophil degranulation molecules, elastase and
lactoferrin (395). They found that levels of IL-8 and elastase were higher in patients with
DSS than patients without DSS. Furthermore , Huang et al reported that IL-6 and IL-
protein levels were higher in sera from patients with DHF than in DF patients or patients
with other febrile ilnesses (21). These studies suggest that there is a correlation between
chemokine production and disease severity in patients infected with DENV.
Due to the lack of an animal model for DHF, most of the work investigating
primary target cells and potential mechanisms of pathogenesis has been done in vitro.
Many cell types have been analyzed for chemokine secretion following DENY infection.
In vitro infection of the human myeloid cell line , K562 , has been reported to induce
secretion of MIP- la and MIP- (396). Bosch et al found that primary human monocytes
secreted IL-8 upon infection with DENY (4). Chen et al analyzed the kinetics of
cytokine and chemokine levels in supernatants from DENV infected
monocytes/macrophages (398). They found secretion of MIP- , RANTES and IL-
from DENY infected monocytes/macrophages within hours of DENY infection , with
levels peaking on day 2 , day 4 and day 7 post infection, respectively, whereas viral yields
peaked at 42 hours post infection. In addition, Chen et al found that IL- IJ), TNFa, IFNa
and IL- 12 production by DENY infected monocyte/macrophages peaked at day 2 , day 3,
day 4 and day 7 post infection , respectively. They proposed that chemokines were
initially induced to attract cells to the sites of infection and that prolonged chemokine
expression in combination with cytokines functionally matured the infiltrating cells.
Endothelial cells are important for maintaining vascular integrity and have been
investigated for their role in plasma leakage during DENY infection. Talavera et al
found an increase of permeability of HMEC- l (a human microvascular endothelial cell
line) monolayer infected with DENY for 48 hours , which correl?ted with actin
cytoskeleton rearangements (5). Furthermore , addition of IL-8 showed effects similar to
DENY infection on permeability and actin reorganization.
Endothelial cells have also been reported to support DENV infection and secrete
chemokines. Avirutnan et al reported that primary endothelial cells derived from human
umbilical cord veins (HUVEC) could be infected with DENV and induced RANTES
expression (6). Huang et al reported that DENV-infected HUVECs induced IL-6 and IL-
8 but not IL- IJ) (21). In addition, inhibition of DEN V replication with ribavirin inhibited
IL-6 and IL-8 secretion from DENV-infected HUVECs. It has also been reported that a
DENY-infected endothelial cell line, ECV304 , has an increase in IL-8 and RANTES
protein and mRNA (4 6). Bosch et al reported that DENV-infected ECV304 cells
induced IL-8 primarily through NF1d rather than NF-IL-6 (c/EBP) (4). These studies
indicate that DENV can directly infect endothelial cells. Furthermore, infection of
endothelial cells results in secretion of mediators that may be directly involved in altering
the vascular wall. In addition, the production of chemoattractants by endothelial cells can
attract cells to the site of infection, which may themselves produce mediators involved in
vascular leakage.
Mast cells have also been analyzed for their role in the pathogenesis of DENV
infection. Tuchinda et al reported an increase in histamine levels in urine from patients
with DHF , suggesting activation of mast cells (399). In addition, the mast cell line,
KU812 , expresses Fc receptors and was shown to be infected with DENV in the presence
of nonneutralizing antibody and produce IL-6 and IL- (400). In another study, King et
al found that KU812 cells produce RANTES , MIP- la and MIP- but not IL-8 upon
antibody-enhanced DENV infection (401). Furthermore , stimulation of KU812 cells with
the inflammatory cytokines IL- and IL-6 did not significantly induce RANTES
expression , indicating that RANTES expression is not due to induction of other
cytokines. In the same study, mast cells cultured from cord blood expressed RANTES
and MIP- during antibody-enhanced DENV infection. These results suggest that mast
cells may also be involved in the pathogenesis of DENV infection.
As previously mentioned, liver involvement has been seen in patients with DHF.
Lin et al have shown that liver cell lines can be productively infected with DENV and
induce cytopathic effects (143). In another study they reported that DENV induced
RANTES protein and mRNA in liver cells by 36 hours post infection (397). Analysis of
the RANTES promoter by luciferase reporter assays and electrophoretic shift mobility
assays identified protein binding to the c/EBP and NFKB sites within the RANTES
promoter to be important for RANTES induction in liver cells (397).
In summary, many cell types have been analyzed for their ability to support
DENV replication and induction of cytokines/chemokines. However, a comprehensive
study of chemokine induction by DENV infection of multiple cell types and primary
monocyte- derived DCs has not been done. In addition, the mechanism(s) of chemokine
induction by DENV has not been fully defined.
N. OBJECTIVES OF THESIS
Previous reports had shown that DENV infection could induce chemokines 
vivo and in vitro. It had been suggested that chemokine production could contribute to
DENV disease , implying that inhibition of chemokine production could be of therapeutic
value. However, little was known about the mechanism of chemokine induction during
DENV infection. Other viral systems such as HCV and HIV had shown that individual
viral proteins could induce chemokine production. We speculated that DENV could also
induce chemokine production through the action of specific viral proteins. The objective
of this thesis was to analyze the mechanism by which DENV induces chemokine
production. In particular, we hypothesized that an individual DENV protein(s) can
induce chemokine expression.
The specific aims of this thesis are as follows:
1. Analyze chemokine induction by DENV in different human cell types.
a. Characterize chemokine induction in both continuous cell lines and primary
monocyte-derived dendritic cells.
b. Identify transcription factors involved in DENV induced chemokine
induction.
2. Analyze the effects of pharmacological inhibitors of cytokine pathways on
chemokine induction during DENV infection.
3. Define the involvement of individual dengue viral protein(s) in chemokine induction.
a. Identify DENV protein(s) involved in the induction of chemokines.
b. Characterize transcription factors involved in the induction of chemokines by
viral proteins.
CHAPTER II:
MATERIALS AND METHODS
A. CELLS AND CELL LINES
HepG2 (A TCC, Manassas, VA), a human hepatocarcinoma cell 
line (402), and
Vero cells (an African green monkey kidney cell line; A TCC, Manassas, VA) were
maintained in Minimum Essential Medium supplemented with 10% fetal bovine serum
(FBS) (GIBCO, Grand Island, NY), 1.0 mM sodium pyruvate
, 0. 1 mM nonessential
amino acids, penicill (lOOU/ml), and streptomycin (lOOllg/ml). 
HEK293 (ATCC,
Manassas, V A) and HEK293A (Invitrogen, Carlsbad, CA), human embryonic kidney cell
lines (403), were maintained in Dulbecco s Modified Eagle Medium supplemented with
10% FBS, O. lmM nonessential amino acids, penicill
(IOOU/ml), and streptomycin
(lOOllg/ml). ECV304 cells (transformed human).:lrge-vessel umbilical cord endothelial
cells) were grown in M199 medium (Life Sciences) supplemented with 10% FBS,
penicilin (100 U/ml), and streptomycin (100 mg/ml). K562 (ATCC, Manassas
, VA), a
chronic myelogenous leukemia cell line, U937
, a myelomonocyti cell line , and Thp-
an acute monocytic leukemia cell line, were maintained in RPMI 1640 medium
supplemented with 10% FBS, penicilin (100 U/ml), and streptomycin (l00 
mg/ml).
B. DENDRITIC CELLS
PBMC were obtained by centrifugation using Accuspin tubes (Sigma-
Aldrich, St.
Louis, MO). CD14+ monocytes were isolated by positive selection using magnetic cell
sorting (MACS), according to the manufacturer s protocol (Milteyl Biotec, Auburn, CA).
The CD14 positive cells were cultured in RPMI 1640 supplemented with 10% fetal
bovine serum, rGM-CSF (800u/ml) and rIL-4 (500u/ml) for 5-
7 days , changing half the
media and adding cytokines every other day. DCs were stained to assess purity with
lineage markers CD3 , CD14, CD16 , CD56 , and CD20 (FITC) , CDla (PE) and HLA-
(PerCP) and analyzed by FACS. DCs were:; 85% pure.
C. ANTIBODIES AND CYTOKINES
Fluorescein isothiocyanate (FITC)-conjugated DEN V complex specific
monoclonal antibody (clone M8051125) was obtained from Fitzgerald Industries
International , Inc. DEN2V specific monoclonal antibody was derived from a hybridoma
cell line , 3H5- 1 (ATCC, Manassas, VA). LPS (1 f.g/ml), PMA (100 ng/ml), ionomycin (1
f.g/ml), and polyI:C (100 f.g/ml) were obtained from Sigma-Aldrich, St. Louis, MO.
IFNa2b (1000 Vlml) was obtained from R& D systems, Minneapolis , MN.
D. DEN2V PROPAGATION
DEN2V strain New Guinea C was used for infection. DEN2V New Guinea C was
received from Dr. Walter E. Brandt of the Walter Reed Army Institute of Research
Washington, DC. The virus was propagated in Aedes albopictus cells (C6/36) 
previously described (404). The titers of the virus pools were determined by fluorescent
focus assay in CVl cells (405).
E. INFECTION WITH DEN2V
Cells were infected with DEN2V strain New Guinea C (NGC) as previously
described (406) at a multiplicity of infection (MOl) of 1 , 5 or 10 for 2 hours at 37 C. For
assays assessing chemokine protein levels by ELISA , supernatants were harvested for
each time point , and fresh media was added to the cells.
Cells were fixed with 1 % paraformaldehyde and stained for DENV antigen by
indirect immunofluorescence (IF) on various days post infection, using 3H5 as the
primary antibody and FITC-conjugated goat anti-mouse immunoglobulin G antibody
(Sigma-Aldrich , St. Louis , MO) as the secondary antibody. For experiments using direct
immunofluorescence , the DENV complex-FITC conjugate antibody was used. The
percentage of infected cells was assessed using flow cytometry.
F. VIRUS INACTIVATION
DEN2V was inactivated by ultraviolet (UV) light. The UV light source was a
Philips TUV 30W G30T8 UV -C light bulb. The virus was exposed at a distance of 15
cm for 30 minutes at room temperature. Alternatively, DEN2V was heat inactivated at
C for 30 minutes.
G. RNA ISOLATION
Total RNA was prepared using the RNeasy kit (Qiagen, Valencia CA) following
the manufacturer s instructions. For RT-PCR , RNA was treated with DNase according to
the manufacturer s protocol (Qiagen, Valencia, CA).
H. RIBONUCLEASE PROTECTION ASSAY
The human chemokine multiprobe template set (hCK-5) was used to make the
radiolabeled probe according to the manufacturer s protocol (Riboquant , Pharmingen
San Diego, CA). The RNase protection assay was perfonned according to the
manufacturer s protocol (Torrey Pines Biolabs , Inc. , La Jolla, CA). Briefly, equal
amounts of total cellular RNA were hybridized to the 
Iabeled hCK-5 riboprobe
cocktail. The hybridized RNA was then digested with RNase A. The RNA was
precipitated and then electrophoresed on a denaturing acrylamide gel and the bands were
detected by autoradiography. Specific chemokine bands were identified on the basis of
their individual migration patterns in comparison with the undigested probes. The bands
were quantified by densitometric analysis using a Storm 820 phosphoimager and Image
Quant densitometric software (Amersham, Piscataway, NJ). GADPH and L32 were used
as internal controls.
1. ELISAS
MIP- I ex, MIP- , MCP- , IL- , and RANTES protein concentrations were
determined in cell culture supernatants using commercially available ELISA kits
according to the manufacturer s instructions (R&D systems , Minneapolis , MN).
J. QUANTITATIVE RT-PCR
Two hundred nanograms of total cellular RNA was used to synthesize cDNA
using Orniscript RT and oligo dT primers following the manufacturer s protocol
(Qiagen, Valencia, CA). PCR was performed in triplicate using TaqMan IL- 8 and 
actin primers and probes (Applied Biosystems , Foster City, CA) and the Gene Amp 5700
Sequence Detection System. For quantitation of mRNA , a standard curve of control
DNA was generated , and samples were normalized to the endogenous -actin control.
The ratios of gene expression in infected or transfected cells versus uninfected or
untransfected cells , respectively, were calculated.
For quantitation of DEN2V RNA from supernatants of virus-infected cells, cDNA
was synthesized from isolated total RNA using Multiscribe Reverse Transcriptase
(Applied Biosystems , Foster City, CA) and the reverse DEN2V primer
(5' CATTCCATTTTCTGGCGTCT3' ) following the manufacturer s instructions. PCR
was performed using the Taqman Universal PCR master mix and DEN2V forward
(5' AAGGTGAGATGAAGCTGTAGTCTC3' ) and reverse primers and a DEN2V
specific probe (6FAMCTGTCTCCTCAGCATCATTCCAGGCATAMRA) and the
GeneAmp 7300 sequence detection system (Applied Biosystems , Foster City, CA).
Quantitation of viral RNA in genome copies per mililiter was performed using a
standard curve of DEN2V RNA.
K. PBMC SAMPLES FROM PATIENTS WITH ACUTE DENV VIRUS INFECTIONS
Serial PBMC samples were studied from 26 children who participated in a
prospective study of acute DENV infection (16 with DF and 10 with DHF) in Thailand
(407). Patients were enrolled in the study if they presented within 72 hours of the onset of
fever. Blood samples were collected daily until 1 day after defervescence. Convalescent
samples were taken 8 to 10 days after enrollment. "Fever day " were assigned
retrospectively as described , where fever day 0 refers to the day of defervescence. As
described previously (396), PBMC (approximately 2x10 cells) isolated from whole
blood using Histopaque (Sigma-Aldrich, St. Louis , MO) were resuspended in 1 ml of
buffer (4M guanidine isothiocyanate , 40 mMTris-HCl pH 6.4 17 mM EDTA pH 8.
1 % Triton X- 100), frozen at - C and shipped on dry ice. Total RNA was prepared
using the RNeasy kit (Qiagen , Valencia, CA) substituting the lysing buffer for Buffer
RLT.
L. PHARMACOLOGICAL INHIBITORS
4-(4- fluorophenyl)- 2- 4-methy Isulfiny Ipheny 1)-5-( 4-pyridyl)irndazole
(SB203580) (408-410), rolipram (359, 411), ammonium pyrrolidinedithiocarbamate
(PDTC) (412), indomethacin (413), and 9a-fluoro- 16a-methyl- , 17a, 21-trihydroxy-
1,4-pregnadiene- 20-dione (dexamethasone) (414) were purchased from Sigma-Aldrich
Co. , St. Louis , MO. Cells were infected with DEN2V at an MOl of 5 for 2 hours at 37
C as above or in the presence of 10 j.M SB203580 , 100 j.M rolipram, 250 nM
dexamethasone , 250 nM PDTC , or 30 f.M indomethacin. These drug concentrations
were selected based on their ability to inhibit cytokine production in previous studies
cited above. The media was changed at time points specified with fresh media containing
the same drugs. The cell monolayer in drug-treated wells was assessed by microscopy
and compared with untreated DEN2V infected cells.
M. PLASMIDS
A plasmid expression the DEN2V replicon was kindly provided by Dr. Andrew
Dayton (415). This replicon contains the genes for expression of C and the nonstructural
proteins and is expressed under the control of the CMV promoter. Four luciferase
reporter constructs containing the IL-8 promoter were generously provided by Dr.
Naofumi Mukaida (Kanazawa University, Japan): one with wild-type (WT) binding sites
for NFKB , AP- l and c/EBP, and the other three with mutant binding sites for NFKB
(GGAATTTCCT to TAACTTTCCT from -SOto -71), AP- l (TGACTCA to TATCTCA
from - 126 to - 120) orc/EBP (CAGTTGCAAATCGT to AGCTTGCAAATCGT from-
94 to -81) (416). Luciferase reporter constructs containing tandem repeat binding sites
for NFKB , AP- l and c/EBP were obtained from Strategene (La Jol1a CA). Plasmids
expressing signaling molecules Mal, MEKKl , or TBKI and the luciferase reporter
construct containing the ISRE of the IFIT2 gene were generously provided by Dr. Kate
Fitzgerald (UMass Medical School , MA) (181 417). The pcDNA3. 1 plasmid was
obtained from Invitrogen, Carlsbad , CA.
Primers were designed for PCR amplification and cloning of each of the DEN2V
genes (Table 11-1). Each 5' and 3' primer contained attBl and attB2 sequences
respectively, for homologous recombination into the Gateway entry vector pDONR201
(Invitrogen , Carlsbad, CA). The prM , E and NS 1 forward primers included the putative
leader sequences (88 418).
PCR was performed using rTth DNA polymerase (Applied Biosystems , Foster
City, CA) and DEN2V infectious clone as the template (kindly provided by Dr. Barry
Falgout, FDA (419)). The PCR products were cloned into pDONR201 by homologous
recombination using Gateway Technology following the manufacturer s instructions.
Mammalian expression vectors were made by homologous recombination of each
DEN2V gene into the pDEST40 vector , which contained a carboxy-terminal V5 epitope
and 6XHis tag, or pDEST47 , which contained a carboxy-terminal GFP tag, as described
in the Gateway Technology manual (Invitrogen, Carlsbad, CA). The identities of the
clones were confirmed by DNA sequencing.
N. TRANSFECTIONS
HEK293A cells were transfected using Effectene (Qiagen , Valencia, CA)
following the manufacturer s instructions. Briefly, HEK293A cells were seeded onto 6
well plates at 2X10 cells per well 24 hours before transfection. To transfect, 0. g of
DENV protein expressing plasmid and 0.2 g of lacZ expressing plasmid were diluted in
EC buffer (Qiagen , Valencia, CA) for each condition. In addition , 6.4 l of Enhancer
(Qiagen , Valencia , CA) was added to the mixture and incubated for 2 minutes at room
temperature. The mixture was spun down; 8 l of Effectene (Qiagen , Valencia, CA) was
added and incubated for 5 minutes at room temperature. Growth media was added to the
mixture and the mixture was added to the cells. Transfection efficiency was
approximately 30% as assessed by galactose staining following the manufacturer
protocol (Invitrogen , Carlsbad , CA).
O. WESTERN BLOT
Laemrli sample buffer containing 350mM DTT was added to DEN2V infected
Vero cells collected 48 at hours post infection and prM-E transfected HEK293 cells and
supernatants collected at 24 hours later. Samples were heated at 90 C for 10 minutes and
run on a Criterion 10% Tris-HCL SDS-PAGE gel (Bio-Rad Laboratories , Hercules , CA)
along with the MagicMark standard (Invitrogen , Carlsbad , CA) to detect band size.
Samples on the gel were transferred to a nitrocellulose membrane following
manufacturer s recommendations (Bio-Rad Laboratories , Hercules , CA). The E protein
was detected using the WesternBreeze chemiluminescent western blot Immunodetection
kit (Invitrogen , Carlsbad , CA). The 3H5 antibody, which detects DENV E protein , was
used as the primary antibody. X-ray film was exposed to the membrane to detect E
specific bands.
P. LUCIFERASE REPORTER GENE ASSAY
HEK293A cells were plated in a 96 well plate at 2X10 cells per milliliter. After
24 hours , the cells were transfected with reporter plasmids and/or expression p1asmids
using Genejuice according to the manufacturer s protocol (Novagen , EMD Biosciences
Inc , San Diego, CA). Twenty four hours (for plasmids) and 72 or 96 hours (for virus)
later, cells were lysed, and the luciferase activity was determined. A Renilla reniformis
luciferase reporter under the control of the herpes simplex virus thymidine kinase
promoter, pRL- , was used as an internal control to normalize reporter gene activity.
Luciferase activities were determined by a luminometer using the dual-luciferase reporter
assay according to the instructions of the manufacturer (Promega Co. , Madison , WI). All
conditions were tested in triplicate. At least two independent experiments were performed
for each assay.
Q. CONFOCAL MICROSCOPY
The GFP tagged NS5 or NS3 expression plasmids were transfected into 293A
cells using Genejuice following the manufacturer s protocol (Novagen, EMD
Biosciences, Inc , San Diego, CA). Cells were washed with IX Phosphate Buffered
Saline (PBS) and fixed in 100% cold ethanol for 5 minutes. The cells were air dried and
mounted using VectaShield from Vecta Laboratories which contains the DAPI (4' ,
diamidino- phenylindole) nuclear stain. Cells were analyzed using the Leica TCS SP2
AOBS confocal microscope and Leica Confocal Software (LCS; Leica Microsystems
Bannockburn , IL.)
Table II- I. Primers used for cloning of DEN2V genes.
(forward)
(reverse)
prM
(forward)
prM
(reverse)
(forward)
(reverse)
NSl
(forward)
NSl
(reverse)
NS2A
(forward)
NS2A
(reverse)
NS2B
(forward)
NS2B
(reverse)
NS3
(forward)
NS3
(reverse)
NS4A
(forward)
NS4A
(reverse)
NS4B
(forward)
NS4B
(reverse)
NS5
(forward)
NS5
(reverse)
primer names indicate the gene amplified for cloning.
Primer Sequence (5'
GGGGACAAGTTGT ACAAAAAAGCAGGCTTCACCATGAAT AACCAACGAAAAAAGGCGAG
GGGGACCACTTTGT ACAAGAAAGCTGGGTCCGCCA TCACTGTTGGAA TCAGC
GGGGACAAGTTTGT ACAAAAAAGCAGGCTTCACCA TGAGAACTGCAGGCA TGA TCA TT ATGCTGA TTC
GGGGACCACTTTGT ACAAGAAAGCTGGGTCCT A TGTCA TTGAAGGAGCGACAGCTG
GGGGACAAGTTTGT ACAAAAAAGCAGGCTTCACCA TGAGAGCCCTGA TTTTCA TCTTACTGACAG
GGGGACCACTTGT ACAAGAAAGCTGGGTCCT AGGCCTGCACCA TAACTCCCAAA TAC
GGGGACAAGTTGT ACAAAAAAGCAGGCTTCACCA TGAA TTCACGCAGCACCTCACTG
GGGGACCACTTGT ACAAGAAAGCTGGGTCGGCTGTGACCAAGGAGTTGAC
GGGGACAAGTTGT ACAAAAAAGCAGGCTTCACCA TGGGACA TGGGCAGA TTGACAACTTTTCA
GGGGACCACTTTGT ACAAGAAAGCTGGGTCCCTTTTCTTGTTGGTTCTTGAAAGGGTTG
GGGGACAAGTTTGT ACAAAAAAGCAGGCTTCACCA TGAGCTGGCCACTAAA TGAGGCT A TCA
GGGGACCACTTGT ACAAGAAAGCTGGGTCCCGTTGTTTCTTCACTTCCCACAG
GGGGACAAGTTTGT ACAAAAAAGCAGGCTTCACCA TGGCTGGAGT A TTGTGGGA TGTCC
GGGGACCACTTGT ACAAGAAAGCTGGGTCCTTTCTTCCAGCTGCAAACTCCTTGAA TT
GGGGACAAGTTTGT ACAAAAAAGCAGGCTTCACCA TGTCCCTGACCCTGAACCTAA TCACA
GGGGACCACTTGT ACAAGAAAGCTGGGTCTCTTTTCTGAGCTTCTCTGGTTGCTTTTG
GGGGACAAGTTGT ACAAAAAAGCAGGCTTCACCA TGGCAGGAGCGGGCA TCA TGAAAA
GGGGACCACTTGT ACAAGAAAGCTGGGTCCCTTCTCGTGTTGGTTGTGTTCTTCA T
GGGGACAAGTTGT ACAAAAAAGCAGGCTTCACCA TGGGAACTGGCAACA T AGGAGAGAC
GGGGACCACTTTGT ACAAGAAAGCTGGGTCCCACAGGACTCCTGCCTCTT
Bold sequence is the DEN2V sequence and the underlined sequences are added stop
codons.
CHAPTER III:
ANALYSIS OF CHEMOKINE INDUCTION BY DENGUE VIRUS
A. CHEMOKINE PRODUCTION DURING DEN2V INFECTION OF CELL LINES.
Previous studies had shown that endothelial cells, liver cells , mast cells
monocytes and dendritic cells can be productively infected with DENV. However, these
studies did not analyze chemokine production from multiple target cell lines or primary
monocyte-derived DCs. We hypothesized that distinct profiles of chemokine secretion
can be induced by DEN2V infection of various cell types in vitro. In addition , we wanted
to find a cellline(s) that would facilitate in vitro studies of DENV induced chemokine
induction.
We analyzed chemokine induction by DEN2V infection in various cell lines
including myelomonocytic cell lines U937 , K562 and Thp- , the hepatoma cell line
HepG2 , the endothelial cell line ECV304 , and the embryonic kidney cell line HEK293.
Of the cell lines tested , HepG2 , HEK293 and K562 cells were most susceptible to
DEN2V infection as assessed by flow cytometry. HepG2 cells were infected 25% by day
1 and 50% by day 6 with DEN2V with an MOl of 1 (data not shown). Thirteen percent
of ECV304 cells were infected by day 1 and 6% were infected by day 6 with an MOl of
1. HEK293 cells were infected 37% by day 1 with DEN2V with an MOl of 1. By day 4
post infection , HEK293 cells were infected only 3% with extensive destruction of the
monolayer. K562 cells were infected 60% by day 1 and 25% by day 6 with an MOl of
10. Infection of Thp- l and U937 cells with DEN2V at an MOl of 10 was undetectable by
!:'
flow cytometry with or without enhancing antibody. In comparison , DEN2V RNA levels
in culture supernatants of HepG2 and HEK293 cells reached maximum values (-
genome copies/ml) by 48 hours post infection (Figure III- I).
The secretion of chemokines in HepG2 , HEK293 and ECV304 cell lines peaked
late in infection , between days 3 and 5. DEN2V infected HepG2 cells secreted IL-
RANTES , MIP- la and MIP- (Table III-I). Only IL-8 and RANTES were secreted in
DEN2V -infected HEK293 cells. Although the percentage of infected ECV304 cells was
low , RANTES expression increased during DEN2V infection by day 2 when compared to
mock infected cells. ECV304 cells have previously been reported to induce IL-8 upon
DEN2V infection (4). Although K562 cells were readily infected with DEN2V, none of
the chemokines tested were detected. These results indicate a unique chemokine
induction profile for each cell type during DEN2V infection. In addition, these data
suggested that HepG2 and HEK293 cells were good candidate cell lines for in vitro
studies of DEN2V induced chemokines because they were productively infected and
produced multiple chemokines.
To assess whether protein expression of each chemokine was regulated at the
transcriptional level or during translation, chemokine mRNA levels in HepG2 cells were
analyzed by ribonuclease protection assay (RPA) (Figure 111-2). DENV infection
induced the expression of IL- , RANTES , MIP- l a, MIP- and IPl 0 mRNAs. The
levels of mRNA peaked between days 3 and 5 , which was similar to the kinetics of
protein expression (Figure 111-2 and Table III-I). To quantify the induction ofIL-
mRNA by DEN2V infection , real time fluorogenic RT-PCR was performed. As seen in
figure 111- , IL-8 mRNA levels peaked at day 4 post infection.
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Table 111-1. Chemokine production from DEN2V infected HepG2, HEK293 and
ECV304 celllines
IL-
RANTES
MIP-
MIP- 1 B
HEK293 IL-
RANTES
ECV304 RANTES
a Results are in pg/ml
HepG2
Day 1 
D2V Media11 
48 
D2V Media44 73 480 22 
13 
D2V Media97 427 873 67 18 64 35 
b Cell1ines were infected with DEN2V NGC at an MOl of 1.
Representative result of three independent experiments.
d ND
, not determined
D2V Media164 1350 819 284 69 110 61 
D2V Media168 
1721 669 623 138 
N D N D48 
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Figure III-I. Production ofDEN2V progeny during in vitro infection of HepG2 and
HEK293 cells. DEN2V RNA levels in supernatants of infected cell lines were assessed
by quantitative real time RT-PCR. The data are expressed as mean:! standard deviation
from a representative experiment done in triplicate.
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Figure 111-2. Chemokine mRNA expression in HepG2 cells infected with DEN2V.
HepG2 cells were infected with DEN2V at MOl of 1. Total RNA was isolated for each
time point after viral infection. The figure is representative result for a minimum of two
separate experiments. Detection and quantification of the indicated human chemokine
mRNAs were analyzed by ribonuclease protection assay as outlined in the Materials and
Methods. P denotes probe lane, D denotes day, (+) indicates infection with DEN2V and
(-) indicates mock infection.
60E-
C: 1.40E-01 -
20E-
Cj 1.00E-
o 8.00E-
:; 6.00E-
00E-
00E-
OOE+OO
,.," """" ''' 
Day Day 2 Day 4 Day 5 Day 6 Day 7
-. 
DEN2V
11.. Uninfected
Figure 111-3. IL-8 mRNA induction in HepG2 cells infected with DEN2V. IL-
mRNA levels in DEN2V infected HepG2 cells were assessed by quantitative fluorogenic
RT -PCR. Results were normalized to endogenous -actin RNA levels.
B. CHEMOKINE INDUCTION FOLLOWING IN VITRO DENV INFECTION OF
PRIMARY HUMAN CELLS AND PBMC IN VIVO.
The above studies confirmed the induction of chemokine expression by DENV
infection in human cell lines. However, there has been comparably little data on
chemokine induction by DENV in non-transformed human cells. Chemokine induction
has been shown in primary monocytes following DEN V infection (4 , 398). Since DCs
have also been proposed as an important target for DENV infection 
in vivo, 
performed a single preliminary experiment to analyze chemokine induction from DEN2V
infected dendritic cells. Monocytes were isolated from PBMC and were cultured for 7
days with IL-4 and GM-CSF to generate myeloid DCs (135 , 137). The cells were stained
for HLA- , lineage markers (CD3 , CD20 , CD56 and CD14) and CD1a and sorted by
flow cytometry. Approximately 85% of the cells were phenotypically dendritic cells
(HLA-DR+ , lineage- and CDla ) (Figure III-4). The DCs were infected with DEN2V at
MOls of 0. , 1 and 10. The cells were harvested on day 5 post infection to determine the
percentage of cells infected by flow cytometry. As seen in figure III-5 - 1 % of the cells
were infected by day 5 post infection for MOl of 0. 1 whereas - 18% of the cells were
infected for MOl of 10. Culture supernatants were collected days 1 , 3 and 5 post
infection for analysis of chemokine levels by ELISA. IL- , RANTES , MIP- , and
MIP- levels were significantly higher in cultures of infected DCs by day 1 post
infection (Table III-2). The levels of chemokines decreased but remained higher than
background through day 5. MCP- l1evels were higher in cultures of DEN2V infected
cells only at day 1 post infection. A substantial amount of cell death occurred by day 5 in
DEN2V -infected cultures and may explain the decrease in chemokine levels in the
supernatants. Although the analysis of chemokine secretion from DEN2V - infected
dendritic cells was obtained from a single PBMC donor, the results indicate that
chemokine induction by DEN2V also occurs in primary cells that are potential targets of
DENV infection in vivo.
To determine whether IL- 8 gene expression also occurs in vivo during DENV
infections , we analyzed IL-8 mRNA levels in PBMC collected from 26 subjects with
acute DENV infections using quantitative RT-PCR. All subjects had DENV viremia
detected by RT-PCR at the time of entry into the study (396). IL-8 mRNA levels were
numerically expressed as C values relative to -actin mRNA levels. As shown in figure
III- , IL-8 mRNA was detected in PBMC from all subjects tested. Mean IL-8 mRNA
levels were highest later in infection towards the end of the febrile period (fever day - 1 to
0), particularly in subjects with DHF. However, there were no statistically significant
differences in IL-8 mRNA levels between subjects with DF and those with DHF.
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Figure 111-4. FACS staining for phenotypic markers expressed on dendritic cells.
CDI4+ monocytes isolated from PBMC were cultured for 7 days with rIL-4 and GM-
CSF. DCs were infected at an MOl of DCs-as described in the MATERIALS AND
METHODS. After 7 days , DCs were harvested and stained for HLA- , lineage
markers and CD 1 a to assess the percentage of cells that have a DC phenotype.
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Figure 111-5. DEN2V infection of monocyte-derived dendritic cells. DCs were
infected at A. MOl of 0. 1 B. MOl of 1 C. MOl of 10 D. C6/36 supernatant treated cells
(ctrl). Day 5 post infection, DCs were harvested and stained with DEN2V specific
antibody as described in MATERIALS AND METHODS.
Table llI-2. Chemokine production from DEN2V-infected DCs.
Day Condition IL-8* RANTES* MIP-la* MIP- lf3* MCP-
media 400 180 520
C6/36 220 11.2 300 440
DEN2V 0. 1 ** 13920 11960 8000 16060 2180
DEN2V 1 ** 3440 12700 8980 17300 2100
DEN2V 10** 27940 8300 9740 15320 1340
media 1780 114 400 2060
C6/36 1060 180 1740
DEN2V 0.1 ** 8040 6040 2140 3060 1200
DEN2V 1 ** 11640 8420 2820 4440 1720
DEN2V 10** 20500 7020 3960 3660 1020
media 2040 108 640 4600
C6/36 1080 120 380 3160
DEN2V 0. 1 ** 17600 840 440 640 580
DEN2V 1 ** 4380 1460 800 1580 640
DEN2V 10** 6640 2440 1240 860 200
concentration in pg/ml
** 0. , 1 and 10 refer to MOIs
. DF . DHF -Means
1 0. 1- I'" .
. 8
- i
...
15.
a: -20.
25.
Fever day
Figure 111-6. IL-8 gene expression in PBMC of patients with acute DENV infection.
Total RNA was isolated from serial PBMC samples obtained from 16 subjects
with dengue fever (DF o) and 10 subjects with dengue hemorrhagic fever (DHF, 0). IL-
and -actin mRNA levels were measured by quantitative RT-PCR using TaqMan primers
and probes. IL-8 mRNA levels are expressed as the difference in C between -actin and
IL-8. The mean levels of IL-8 mRNA in each group are indicated by the (-
C. IL-8 INDUCTION REQUIRES REPLICATION COMPETENT VIRUS AND IS
NOT DUE TO IFNa.
To assess whether the IL-8 expression in DEN2V infected HepG2 cells was due
to DEN2V antigen or replicating virus , DEN2V was heat inactivated or UV inactivated.
The virus was added to HepG2 cells at a (preinactivation) MOl of 1 for 2 hrs at 37 C and
supernatants were collected daily for analysis of IL-8 secretion by ELISA. Viral progeny
was also measured in the supernatants by indirect fluorescent antibody staining.
Supernatants from live DEN2V infected HepG2 cells contained approximately 10
fluorescent focus units per ml (ffu/ml) by Day 3 , whereas infectious DEN2V was not
detected in the supernatants from HepG2 cells treated with UV or heat inactivated virus.
As seen in figure 111- , IL-8 secretion was induced only in cells infected with live
DEN2V , suggesting that replication competent virus is necessary for IL-8 expression.
We considered the possibility that induction of IL-8 in cells infected with DEN2V
was due indirectly to induction of IFNa production. Lipopolysaccharide (LPS), polyl:C
or IFNa treatment of HepG2 cells did not induce RANTES , MIP- la or MCP-
expression (Figure 111-8). In addition, there was no IL-8 induction in HepG2 and
HEK293 cells treated with LPS, polyl:C or IFNa (Figure 111-9). However PMAI
lonomycin treatment induced IL-8 secretion by 3 hours post stimulation in HepG2 cells
and by 8 hrs in HEK293 cells (Figure 111-9). Moreover, IFNa was not produced in either
HepG2 or HEK293 cells in response to DEN2V infection or stimulation with polyl:C
(data not shown). These results suggest that activation of the innate immune system is
not involved in IL-8 secretion during DEN2V infection. Overall , the results indicate that
IL-8 secretion during DEN2V infection is directly due to replication competent virus.
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Figure 111-7. IL-8 expression in HepG2 cells requires replication competent DEN2V.
DENV Heat C6/36
UV and heat inactivated virus , untreated virus (MOl of 1) and C6/36 supernatants were
added to HepG2 cells for 2 hours at 37 C. Supernatants were analyzed for IL-8 protein
by ELISA for days 3, 4 and 5 post infection.
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Figure III-S. Chemokine secretion from HepG2 cells stimulated with LPS, polyI:C,
DEN2V or IFNa. HepG2 cells were infected with DEN2V at an MOl of 1 or stimulated
with 1 Ilg/ml LPS , 100 Ilg/ml polyI:C or 1000 Dim I IFNa2b. Supernatants were
collected each day and analyzed for levels of A. MIP- l a, B. RANTES or C. MCP- I by
ELISA.
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Figure 111-9. IL-8 secretion from HepG2 and HEK293 cells stimulated with LPS,
polyI:C, PMA and ionomycin or IFNa. A. HepG2 and B. HEK293 cells were
stimulated with 1 /-g/ml of LPS , 100 /-g/ml of polyI:C , 100 nglml PMA and l/-g/ml of
ionomycin , 1000 D/ml oflFNa2b or no stimulation (media) for 1 , 3 , 8 or 24 hrs.
Supernatants were analyzed for IL-8 secretion at each time point by ELISA.
D. TRANSCRIPTION FACTORS INVOLVED IN CHEMOKINE INDUCTION
BY DEN2V
To assess transcription factors involved in the induction of IL-8 by DEN2V , we
transfected HEK293A and HepG2 cells with luciferase reporter constructs containing
tandem repeats of the consensus binding sites for the transcription factors c/EBP , AP-
and NFKB , a construct containing a promoter driven by an ISRE site, or constructs
containing the RANTES or IL-8 promoters. In addition to the wt IL-8 promoter, we also
obtained reporter constructs containing mutations in the binding sites for c/EBP
(mtc/EBP), AP- l (mtAP- l) or NFKB (mtNFKB) (416) as described in the MATERIALS
AND METHODS. We tested whether DEN2V infection would activate transcription
from these reporters using a luciferase assay system.
DEN2V infection of HEK293A cells induced transcription from the IL-
promoter 15-fold over uninfected cells (Figure 111- 10). Transcription from the ISRE
driven promoter was induced by DEN2V 13-fold , and the RANTES promoter was
induced 5-fold at 72 hours post infection. The IKK-related kinase TBKI has recently
been shown to phosphorylate and activate IRF-3; overexpression of TBKI induced
transcription from both the ISRE and RANTES promoters (positive control), consistent
with published reports (180, 181) Similarly, overexpression of Mal , the TLR4 adaptor
molecule , induced transcription from the IL-8 promoter (positive control), as previously
reported (417 420).
DEN2V infection of HEK293A cells activated NFKB three fold , AP- l two fold
and c/EBP one and half fold over the control (Figure III- II). In contrast, DEN2V
infection of HepG2 cells activated AP- l approximately three fold over control whereas
there was no detectable activation of the c/EBP or NFKB reporters (Figure III- l 2). These
results suggest that NFKB , AP- I and c/EBP are involved in IL-8 induction during
DEN2V infection of HEK293A cells; whereas AP- l may play the predominant role in
DEN2V infected HepG2 cells. Activation of transcription factors by DEN2V , therefore
appears to be dependent on the cell type that is infected.
Transcription factors have been reported to cooperate with each other to synergize
activation of a promoter (256, 307 , 308). Therefore , we wanted to assess the importance
of each of the transcription factor binding sites within the context of the IL-8 promoter.
In HEK293A cells , activation of each of the mtc/EBP , mtAP- , and mtNFKB IL-
promoters by DEN2V infection of HEK293A cells showed a two fold reduction
compared to the wildtype IL-8 promoter by day 4 post infection (Figure III- l3). These
results suggest that activation of all three transcription factors is needed for full IL-
induction in DEN2V -infected HEK293A cells. In contrast , none of the mutations in the
transcription binding sites within the IL-8 promoter showed inhibition of IL-8 induction
with DEN2V infection of HepG2 cells (Figure III- 14). These results suggest that AP-
may be important but not necessary for IL-8 induction during DEN2V infection of
HepG2 cells. AP- l has been shown to cooperate with NFKB and c/EBP to induce gene
expression such as IL-8 (307). Therefore , the level of activation of each of the
transcription factors may not be as important for IL-8 induction as the ability to interact
with each other.
None of the conditions tested in HepG2 cells activated NFKB , yet studies have
implicated NFKB as the predominant transcription factor involved in chemokine
induction during DENV infection (4). Therefore, to verify that our reporters were able to
be induced we treated HepG2 cells with PMA (phorbol myristate acetate) and ionomycin.
PMA is a potent inducer of protein kinase C (PKC) which catalyzes the phosphorylation
of other proteins within the cell. PMA has been shown to induce IL-8 in keratinocytes
mononuclear cells , osteoblasts , HEp-2 cells (a human epidermallarynxcarcinoma cell
line) and Thp- l cells (a human myelomonocytic cell line) (421-424). We found induction
of transcription from RANTES, IL- , c/EBP , AP- I and NFKB promoters with PMA and
ionomycin treatment, which indicates that HepG2 cells are capable of activating NFKB
(Figure 111- 15).
In summary, the results suggest that the pattern of c/EBP, AP- I and NFKB
activation due to DEN2V infection is dependent on the cell line infected. DEN2V
infection of HEK293A activates mainly NFKB , and to a lesser extent, AP- I and c/EBP
whereas DEN2V infection of HepG2 activates predominantly AP- I. Furthermore , the
lack of NFKB activation in DEN2V - infected HepG2 cells was not due to a defect in the
cell line.
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Figure 111-10. DEN2V activates the ISRE binding site, RANTES and IL-
promoters. HEK293A cells were transfected with luciferase reporter constructs
containing the RANTES or IL-8 promoter or tandem repeat binding sites for ISRE, and
infected 24 hours later with DEN2V at an MOl of 1 , UV inactivated DEN2V or C6/36
supernatants. At 72 hours post infection , luciferase reporter gene activity was measured.
Data were normalized for transfection efficiency based on R. reniformis luciferase
activity and expressed as fold induction relative to C6/36 treated cells for each construct.
There is a statistically significant difference (P -: 0.02) between DEN2V and C6/36
treated cells for ISRE , RANTES and IL-8 reporters using the student t-test. The data are
expressed as mean:! standard deviation from a representative experiment for a minimum
of two separate experiments , each done in triplicate.
8 -
6 -
5 -
-g 4
o c o c c: I\ o c c: I\ o c c: I\ 
IL- clEBP AP- NFKB
Figure 111-11. Activation of transcription factors by DEN2V infection of HEK293A.
HEK293A cells were transfected with luciferase reporter constructs containing the
RANTES or IL-8 promoter or tandem repeat binding sites for c/EBP, AP- 1 or NFKB and
infected 24 hours later with DEN2Vat an MOl of 1 , UV inactivated DEN2V or C6/36
supernatants. At 96 hours post infection , luciferase gene activity was measured. Data
were normalized for transfection efficiency based on R. reniformis luciferase activity and
expressed as fold induction relative to C6/36 treated cells for each construct. There is a
statistically significant difference (P:S 02) between DEN2V and C6/36 treated cells for
IL- , c/EBP AP- 1 and NF1d reporters using the student t-test. The data are expressed as
mean:! standard deviation from a representative experiment for a minimum of two
separate experiments , each done in triplicate.
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Figure 111-12. Activation of transcription factors by DEN2V infection of HepG2
cells. HepG2 cells were transfected with luciferase reporter constructs containing the
RANTES or IL-8 promoter or tandem repeat binding sites for c/EBP, AP- l or NFKB and
infected after 24 hours with DEN2V at an MOl of I. At 72 hours post infection
luciferase gene activity was measured. Data were normalized for transfection efficiency
based on R. reniformis luciferase activity and expressed as fold induction relative to
media for each construct. There is a statistically significant difference 
(P:S 05) between
DEN2V and media treated cells for IL-8 and AP- l reporters using the student t-test. The
data are expressed as mean :t standard deviation from a representative experiment for a
minimum of two separate experiments, each done in triplicate.
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Figure 111-13. Effect ofDEN2V infection on transcription from mutated IL-
promoters in HEK293A cells. HEK293A cells were were transfected with luciferase
reporter constructs containing the IL- , mtc/EBP , mtAP- , and mtNFKB promoters and
infected after 24 hours with DEN2V at an MOl of 1. At 96 hours post infection
luciferase gene activity was measured. Data were normalized for transfection efficiency
based on R. reniformis luciferase activity and expressed as fold induction relative to
C6/36 treated cells for each construct. There is a statistically significant difference 
(P 
01) between DEN2V and C6/36 treated cells for IL-8, mtc/EBP, mtAP- 1 and mtNFKB
reporters using the student t-test. The data are expressed as mean:! standard deviation
from a representative experiment for a minimum of two separate experiments , each done
in triplicate. Mtc/EBP, mtAP- l, and mtNFKB represent the 1 33-1uc plasmid with point
mutations in the NF-IL- , AP- , and NFKB binding sites , respectively.
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Figure 111-14. Effect ofDEN2V infection on transcription from mutated IL-
promoters in HepG2 cells. HepG2 cells were transfected with luciferase reporter
constructs containing the IL- , mtc/EBP, mtAP- , and mtNFKB promoters and infected
after 24 hours with DEN2V at an MOl of 1. At 72 hours post infection , luciferase gene
activity was measured. Data were normalized for transfection efficiency based on 
reniformis luciferase activity and expressed as fold induction relative to media for each
construct. There is a statistically significant difference (P:S 05) between DEN2V and
media treated cells for IL-8 and AP- l reporters using the student t-test. The data are
expressed as mean:! standard deviation from a representative experiment done in
triplicate.
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Figure 111-15. PMA and ionomycin stimulation of HepG2 cells activated
transcription from chemokine promoters and transcription factor reporters. HepG2
cells were transfected with luciferase reporter constructs containing the RANTES or IL-
promoter or tandem repeat binding sites for c/EBP , AP- l or NFKB. After 24 hours , cells
, -
were stimulated with 100 ng/ml PMA and 1 J,g/ml ionomycin. Celllysates were
harvested for analysis of luciferase activity at 24 hours post stimulation. The data were
normalized for transfection efficiency based on R. reniformis luciferase activity and
expressed as fold induction relative to media for each construct. The data are expressed
as mean:! standard deviation from a representative experiment done in triplicate.
E. ROLE OF NFKB IN DENY-INDUCED GENE EXPRESSION.
DENY infection induces transcription factors NFKB , AP- l and c/EBP, which are
involved in the induction of many genes including chemokines (4 , 397 425-427). It
has been reported that NFKB plays a predominant role in IL-8 induction during DENY
infection (4 , 251). The above data suggested that NFKB plays a role in IL-8 and
RANTES expression in HEK293A cells. To further assess the role of NFKB activation in
induction of IL-8 and RANTES expression by DENY in HEK293A cells , we used a
plasmid that expresses an IKBa dominant negative mutant (IKB super repressor (SR),
IKBa-S32/36A) (181) to block NFKB activation and nuclear localization. As seen in
figure III- , expression of the IKBSR substantially inhibited bo!h IL-8 and RANTES
transcription on days 3 and 4 post infection with DEN2Y. PMA and Ionomycin
treatment also induces NFKB activation which stimulates the production of many
cytokines such as IL- , IL- , TNFa and IFNy (320). As shown in figure III- 17, IKBSR
also significantly inhibited PMA and ionomycin induced IL-8 secretion when compared
to the pcDNA control. These results confirm the importance of NFKB activation for IL-
secretion due to PMA and Ionomycin stimulation in HEK293A cells. In addition , we
show that NFKB is required for IL-8 and RANTES transcription in DEN2Y -infected
HEK293A cells.
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Figure 111-16. Activation ofIL-8 and RANTES promoters in DEN2V-infected
HEK293A cells transfected with IKBSR. HEK293A cells were cotransfected with a
luciferase reporter gene for IL-8 or RANTES and an expression plasmid containing
IKBSR or pcDNA3. 1 control. 24 hours later, cells were infected with DEN2V at an MOl
of 1. Luciferase activity was assessed at A. 72 hours or B. 96 hours post infection. The
data were normalized for transfection efficiency based on R. reniformis luciferase activity
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and expressed as fold induction relative to uninfected cells transfected with pcDNA3.
The data are expressed as mean standard deviation from a representative experiment
done in triplicate.
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Figure 111-17. IL-8 production from PMA and ionomycin stimulated HEK293A cells
transfected with IlCSR plasmid. HEK293A cells were transfected with an expression
plasmid containing IKBSR or pcDNA3. 1 control. Cells were stimulated after 24 hours
with 100 nglml PMA and J.g/ml ionomycin (P/I). At 24 hours supernatants were
collected and analyzed for IL-8 protein levels by ELISA. The data are expressed as mean
:! standard deviation from a representative experiment for a minimum of two separate
experiments , each done in duplicate.
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CHAPTER IV:
EFFECTS OF PHARMACOLOGICAL INHIBITORS ON CHEMOKINE
INDUCTION BY DENGUE VIRUS
A. EFFECTS OF INHIBITORS ON IL-8 AND RANTES INDUCTION BY DEN2V IN
AN EMBRYONIC KIDNEY CELL LINE.
Cytokines play an important role in inflammatory diseases and much effort has
been made to identify pharmacologic inhibitors of proinflammatory cytokine production.
Pharmacological agents are also commonly used to help define signaling pathways
induced by various stimuli. The benefit of these small molecule inhibitors is that they
can access signaling pathways within a cell producing a wide range of anti-inflammatory
theurapeutic potential through inhibition of cytokines/chemokines (330). We wanted to
assess the effect of pharmacological inhibitors of cytokine expression from previous
studies on DEN2V-induced transcription of chemokines in HEK293A. Previously, we
have shown that the embryonic kidney cell line, HEK293A, which is relatively easy to
transfect, induces IL-8 and RANTES upon DEN2V infection by day 3 (Figure IV-I). We
hypothesized that pharmacological inhibitors of cytokines wil inhibit secretion 
chemokines in DEN2V -infected HEK293A cells.
To analyze the effects of pharmacological inhibitors , we transfected HEK293A
cells with RANTES and IL-8 promoter constructs (Figure IV-2). After 24 hours , the cells
were infected with DEN2V at an MOl of 5 in the presence of the pharmacological
inhibitor. Supernatants were taken on days 3 and 4 post infection for chemokine analysis
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by ELISA (Figure IV - 1) and new media was added to the well. The inhibitors were
added to the culture medium each time the media was replaced. In addition , cells were
harvested on day 2 post infection to determine the percent of infected cells by flow
cytometry. As seen in table IV - 1, DEN2V infection rates in SB203580, rolipram and
dexamethasone treated HEK293A cells were similar to untreated DEN2V -infected cells.
In addition , the cell monolayer remained intact through day 4 post infection in each
condition (data not shown).
To characterize the effects these inhibitors had on transcription of IL-8 during
DEN2V infection , we transfected HEK293A with constructs containing tandem repeats
of c/EBP , AP- l and NFKB binding sites (Figure IV-3) and reporters that contain the IL-
promoter with mutations in transcription factor binding sites (Figure IV -4).
1. Treatment of DEN2V - infected cells with SB203580
The production of IL-8 by DEN2V-iIiected cells was -50% lower in the presence
of SB203580 , an inhibitor of the p38 MAPK pathway, when compared to untreated
DEN2V-infected HEK293A cells (Figure IV- I). RANTES production , on the other
hand , was not affected by SB203580 treatment in DEN2V -infected HEK293A cells.
There was a similar inhibition of transcription from the IL-8 reporter in DENV -infected
cells in the presence ofSB203580 treatment on day 3 post infection but not on day 4 post
infection (Figure IV -2). There was -50% increase in the activation of the AP- l promoter
with SB203580 treatment of DEN2V -infected cells compared to untreated DEN2V-
infected cells on day 3 post infection (Figure IV-3 A). However, there was no difference
in the transactivation of c/EBP , AP- l and NFKB in DEN2V infected cells in the presence
or absence of SB203580 on day 4 post infection (Figure IV-3 B). SB203580 treatment
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reduced transcription -80% from the NFKB mutant IL-8 promoter in DEN2V -infected
cells when compared to untreated DEN2V infected cells. Similarly, transcription from
the mutant AP- I IL-8 promoter was reduced -40% when compared to DEN2V infection
without treatment (Figure IV -4). The mutant IL-8 promoter results suggest that
inhibition of NFKB and , to a lesser extent, AP- I binding to the IL-8 promoter is not the
mechanism by which SB203580 inhibits IL-8 transcription during DEN2V infection of
HEK293A cells.
Overall , these results indicate that inhibition of the p38 MAPK pathway by
SB203580 reduces the induction of IL-8 transcription and secretion by DEN2V infection.
This inhibition of IL-8 transcription was not due to a decrease in activation of c/EBP , AP-
1 and NFKB. Inhibition of the p38 MAPK pathway due to SB203580 treatment during
DEN2V infection may activate pathways that can induce the inhibitory forms of
transcription factors such as Fra- l, which binds to AP- l sites (426) or inhibit cooperative
interactions between transcription factors.
2. Treatment of DEN2V -infected cells with rolipram
Treatment of HEK293A cells with rolipram, a PDEIV inhibitor, decreased IL-
and RANTES secretion by -30% when compared to untreated DEN2V-infected cells on
days 3 and 4 (Figure IV - 1). Induction of transcription from the IL-8 and RANTES
promoters was also reduced (Figure IV-2). Transcription from promoters containing
tandem repeats of c/EBP, AP- l or NFKB in rolipram treated DEN2V -infected cells was
not significantly different than untreated DEN2V - infected cells (Figure IV -3).
In contrast, transcription from the mt NFKB IL-8 promoter was significantly
inhibited in rolipram-treated DEN2V -infected HEK293A cells when compared to
;:.
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untreated DEN2V - infected ce))s. No significant difference in activation of the mtc/EBP
or mtAP- l reporters were seen in DEN2V -infected HEK293A cells treated with rolipram
versus untreated DEN2V - infected cells (Figure IV -3). These results suggest that NFKB
activity is not affected by rolipram treatment of DEN2V-infected HEK293A cells.
In summary, these results show that inhibition of PDEIV suppresses expression of
1L-8 and RANTES protein as well as the induction of transcription from the IL-8 and
RANTES promoter. Transcription from the c/EBP , AP- l or NFKB promoters were not
inhibited by rolipram treatment of DEN2V -infected HEK293A cells although
transcription from the mutant NFKB IL-8 promoter was decreased. These results suggest
that inhibition of PDEIV does not inhibit IL-8 and RANTES transcription and protein
expression from DEN2V - infected cells by decreasing activation -of these transcription
factors. Increases in levels of cAMP due to rolipram treatment may activate pathways
that induce inhibitory forms of transcription factors or inhibit cooperative interactions as
previously mentioned above in DEN2V-infected cells treated with SB203580.
3. Treatment of DEN2V -infected cells with dexamethasone
Analysis of chemokine protein levels in the culture supernatants showed an
increase in 1L-8 (-35%) and RANTES (-75%) in DEN2V-infected HEK293A cells
treated with the glucocorticoid, dexamethasone when compared to untreated DEN2V-
infected cells by day 4 (Figure IV - 1). In contrast, dexamethasone treatment reduced IL-
transcription in DEN2V -infected cells -60% by day 4 post infection (Figure IV -2).
There was no significant difference in transcription from the RANTES promoter between
dexamethasone-treated or untreated DEN2V -infected HEK293A cells on day 4.
:?'
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There was no significant difference in the activation of c/EBP- or AP- dri ven
promoters with dexamethasone treatment of DEN2V -infected HEK293A cells when
compared to untreated DEN2V-infected cells on day 4 (Figure IV-3). However, the
activation of the NFKB driven promoter was not above the media control with
dexamethasone treatment (Figure IV-4). However , induction of transcription from the
mutant NFKB IL-8 promoter was inhibited on day 4 with dexamethasone treatment of
DEN2V-infected HEK293A cells compared to untreated DEN2V-infected cells. These
results suggest that dexamethasone treatment of DEN2V -infected HEK293A cells can
inhibit NFKB activation but had no significant effect on AP- I or c/EBP activation.
Overall , these results show that dexamethasone treatment of DEN2V -infected
HEK293A cells increases IL-8 and RATES secretion. This increase in protein
production was not due to an increase in transcription from the chemokine promoters or
activation of the transcription factors c/EBP, AP- I or NFKB. In fact, transcription from
the NFKB promoter and the chemokine promoters was inhibited with dexamethasone
treatment of DEN2V -infected cells. These results suggest that the increase in IL-8 and
RANTES production with dexamethasone treatment of DEN2V infected HEK293A cells
is due to a mechanism other than an increase in transcription , for example , stabilization of
the chemokine mRNA.
4. Treatment of DEN2V -infected cells with PDTC
PDTC treatment of DEN2V infected HEK293A cells decreased IL-8 and
RANTES protein secretion (Figure IV - I) and transcription from the IL-8 promoter
(Figure IV -2) when compared to DEN2V infection without treatment on days 3 and 4.
Transcription from the RANTES promoter was not studied. There was no inhibition of
:'%.
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transcription from AP- 1 or c/EBP promoters , but , there was inhibition of transcription
from the NFKB promoter (Figure IV -3). These results suggest that the inhibiton of
DEN2V -induced IL-8 transcription by PDTC treatment is mediated through inhibition of
NFKB binding. (Note: Analysis of the mutant IL-8 reporter constructs were not done
with PDTC treatment.)
5. Treatment of DEN2V -infected cells with indomethacin
Indomethacin treatment of DEN2V -infected cells substantially decreased IL-
85%) and RANTES (-80%) secretion compared to untreated DEN2V -infected cells
(Figure IV - 1). In addition , the activation of the IL-8 promoter and c/EBP , AP- l and
NFKB reporters by DEN2V infection was inhibited with indomethacin treatment when
compared to untreated DEN2V-infected HEK293A cells (Figures IV-2 and IV-3). This
suggests that multiple pathways are involved in the inhibition of IL-8 and RANTES
induction with indomethacin treatment during DEN2V infection. (Note: Analysis of the
mutant IL-8 reporter constructs were not done with indomethacin treatment.)
109
Table IV -1. Effects of pharmacological inhibitors on rate of DEN2V infection
in HEK293A cells.
Pharmacological Inhibitor % Infection , b
SB203580 (10 11M)
Rolipram (100 11M)
Dexamethasone (250 nM)
Untreated
a % infection was assessed by flow cytometry on day 2 post infection as described in the
MATERIALS AND METHODS.
HEK293A cells were infected with an MOl of 5 with or without inhibitors as described
in the MATERIALS AND METHODS.
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Figure IV-I. IL-8 and RANTES secretion from DEN2V-infected HEK293A cells
treated with pharmacological inhibitors. HEK293A cells were infected with DEN2V
at an MOl of 5 for 2 hours at 37 C with or without addition of inhibitors to culture
medium as described in the MATERIALS AND METHODS. Supernatants were taken
72 or 96 hours post infection for detection of A. IL-8 or B. RANTES protein by ELISA.
The data shown is a representative result from two independent experiments. RP, SB
Dex and Indo represent rolipram, SB203580 , dexamethasone and indomethacin treated
cells , respectively.
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Figure IV -2. Activation of the IL-8 and RANTES promoters in DEN2V infected
HEK293A cells treated with pharmacological inhibitors. HEK293A cells were
transfected with reporter constructs containing the IL-8 or RANTES promoter. After 24
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hours , cells were infected with DEN2V at an MOl of 5 for 2 hours at 37 C with or
without addition of inhibitors as described in MATERIALS AND METHODS. Cell
lysates were harvested for analysis of luciferase activity at A. 72 or B. 96 hours post
infection. The data were normalized for transfection efficiency based on R. reniformis
luciferase activity and expressed as fold induction relative to media for untreated cells.
The data are expressed as mean:! standard deviation for a representative experiment from
a minimum of two separate experiments , each done in triplicate. RP , SB , Dex and Indo
represent rolipram, SB203580, dexamethasone and indomethacin treated cells
respecti vel y.
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Figure IV-3. Activation of the transcription factors cIEBP, AP- l and NF1C in
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HEK293A cells were transfected with reporter constructs containing the IL-8 promoter or
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tandem repeat binding sites for transcription factors c/EBP , AP- I or NFKB. After 24
hours, cells were infected with DEN2V at an MOl of 5 for 2 hours at 37 C with or
without addition of inhibitors as described in MATERIALS AND METHODS. Cell
lysates were harvested for analysis of luciferase activity at A. 72 hours B. 96 hours post
infection. The data were normalized for transfection efficiency based on R. reniformis
luciferase activity and expressed as fold induction relative to media for untreated cells.
The data are expressed as mean:: standard deviation from a representative experiment for
a minimum of two separate experiments , each done in triplicate. RP , SB , Dex and Indo
represent rolipram , SB203580 , dexamethasone and indomethacin treated cells
respecti vel y.
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Figure IV-4. Activation of mutant IL-8 promoters in DEN2V-infected HEK293A
cells treated with pharmacological inhibitors. HEK293A cells were transfected with
vectors encoding a reporter gene for wild type , mtc/EBP, mtAP- l or mtNFKB IL-
promoters and infected with DEN2V at an MOl of 5 after 24 hours. At A. 72 or B. 96
hours post infection , luciferase gene activity was measured. Data were normalized for
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transfection efficiency based on R. reniformis 
luciferase activity and expressed as fold
induction relative to media for untreated cells. The data are expressed as mean:! standard
deviation from a representative experiment for a minimum of two separate experiments
each done in triplicate. RP , SB , Dex and Indo represent rolipram , SB203580,
dexamethasone and indomethacin treated cells, respectively.
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B. EFFECTS OF INHIBITORS ON IL-8 AND RANTES INDUCTION BY DEN2V IN
A HEP A TOCARCINOMA CELL LINE.
Since the studies described above (Chapter III) showed differences in the
activation of transcription factors by DEN2V infection in HEK293A and HepG2 cells,
we wanted to determine if the effects of the pharmacologic inhibitors on the induction of
chemokines and transcription factors we found with HEK293A cells would also occur in
HepG2 cells. We hypothesized that inhibitors of cytokines wil inhibit secretion of
chemokines in DEN2V infected HepG2 cells. We infected HepG2 with DEN2V alone or
in the presence of drugs at an MOl of 5. Supernatants were taken on various days post
infection for chemokine analysis by ELISA (Figures IV -5 and IV -6), cell death was
assessed by microscopy in comparison with untreated cells and cells were harvested to
determine the percent of infected cells by flow cytometry on day 6 post infection (Table
IV-2). In addition , cells were transfected with reporter constructs and infected with
DEN2V at an MOl of 5 24 hours later either in the presence or absence of the inhibitors
(Figures IV- , IV-8 and IV-9). As seen in table IV- , treatment ofDEN2V-infected
HepG2 cells with inhibitors did not significantly affect the rate of infection on day 6 post
infection.
1. Treatment of DEN2V -infected cells with SB203580.
SB203580 treatment of DEN2V infected HepG2 cells did not inhibit IL-8 or
RANTES secretion by day 4 post infection (Figures IV -5 and IV -6). In fact, a significant
increase inIL-8 and RANTES secretion occurred in drug-treated DEN2V -infected
cultures by day 6 post infection when compared to untreated DEN2V infected cells
(Figure IV -5). Furthermore , there was an increase in transcription from the IL-8 and
.. $! .
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RANTES promoters in SB203580 treated cells when compared to untreated DEN2V-
infected HepG2 cells by day 4 post infection (Figure IV -7). In addition , there was little
difference in cell death of the monolayer with SB203580 treatment of HepG2 cells when
compared to untreated cells by day 6 post infection with DEN2V (Table IV -2).
Analysis of transcription factors showed enhanced activation of transcription from
the AP- l promoter in DEN2V -infected HepG2 cells treated with SB203580 when
compared to untreated DEN2V -infected cells , whereas there was no significant change in
the activation of the c/EBP or NFKB reporter (Figure IV -8). SB203580 treatment of
DEN2V -infected HepG2 cells showed moderate inhibition from the mutant AP- l IL-
promoter on day 3 , whereas on day 4 there was a moderate inhibition of transcription
from the mutant c/EBP IL-8 promoter (Figure IV -9). These results suggest that AP-
may playa role in the enhanced induction of transcription of IL-8 and RANTES in
DEN2V -infected HepG2 cells treated with SB203580 when compared to untreated
DEN2V -infected cells.
Overall , the results show that SB203580 treatment of DEN2V-infected cells
increased IL-8 and RANTES secretion , and this was due , in part, to an increase in
transcription from the IL-8 and RATES promoter. In addition, the results suggest that
AP- l is important for induction of transcription in DEN2V -infected cells treated with
SB203580. The enhanced transcription from mutant AP- l reporter suggests cooperative
interaction of AP- l with c/EBP or NFKB.
2. Treatment of DEN2V -infected cells with rolipram.
Rolipram treatment of DEN2V -infected HepG2 cells did not inhibit IL-8 or
RANTES secretion on day 4 post infection when compared to untreated DEN2V -infected
1,'
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cel1s (Figures IV -5 and IV -6). As seen with SB203580, rolipram treatment enhanced IL-
8 and RANTES secretion by day 6 when compared to untreated DEN2V -infected HepG2
cel1s (Figure IV -5). In contrast, rolipram treatment inhibited transcription from the IL-
promoter but not the RANTES promoter in DEN2V -infected HepG2 cel1s (Figure IV -7).
In addition , there was an increase in cell death by day 6 (Table IV -2).
Activation of the AP- l reporter was enhanced with rolipram treatment of
DEN2V -infected HepG2 cells on day 3 post infection when compared to untreated
DEN2V - infected cells (Figure IV -8). However, there was no significant difference in
activation of AP- l promoter on day 4 in DEN2V -infected HepG2 cells treated with
rolipram when compared to untreated DEN2V -infected cells. Furthermore , there was no
significant difference in activation of NFKB and clEBP promoters in DEN2V -infected
HepG2 cells treated with rolipram versus untreated. The IL-8 promoters containing a
mutation in the clEBP , AP- l or NFKB site showed no significant change in transcription
in rolipram-treated DEN2V-infected HepG2 cells on day 3 when compared to untreated
cells (Figure IV -9). However, on day 4 post infection , mutant c/EBP and NFKB
promoters showed a decrease in transcription in DEN2V -infected HepG2 cells treated
with rolipram.
In summary, these data show that enhanced secretion of IL-8 and RANTES in
DEN2V infected HepG2 cells treated with rolipram was not due to enhanced
transcription of mRNA. There was , however, transient enhanced AP- l activation with
rolipram treatment of DEN2V- infected HepG2 cells. This may be an indirect effect from
activation of an upstream factor in the MAPK pathways that can lead to activation of the
p38 MAPK pathway and JNK pathway (see Figure 1- 10). The p38 MAPK has been
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shown to induce factors that can increase mRNA stability. Furthermore , the p38 MAPK
pathway can be activated through the same MAPK pathway as the activation of AP-
(304). The results suggest that inhibition ofPDEIV in DEN2V infected HepG2 cells may
enhance protein expression , perhaps by increasing chemokine mRNA stability or an
increase translation efficiency.
3. Treatment of DEN2V -infected cells with dexamethasone.
Dexamethasone treatment of DEN2V-infected HepG2 cells failed to inhibit IL-
protein expression (Figures IV -5 and IV -6). In addition, there was no significant
difference in the activation of the IL-8 promoter with dexamethasone treatment of
DEN2V -infected HepG2 cells when compared to untreated cells (Figure IV -7). Both
RANTES protein expression and activation of the RANTES promoter were increased
with dexamethasone treatment of DEN2V -infected HepG2 cells in comparison with
untreated DEN2V cells on day 3 (Figures IV -6 and IV -7). However, there was no
significant difference in RANTES protein expression or transcription from the RANTES
promoter in DEN2V -infected cells treated with dexamethasone by day 4.
Dexamethasone treatment of HepG2 cells inhibited cell death of the monolayer due to
DEN2V infection on day 6 (Table IV-2).
Analysis of transcription factors c/EBP, AP- l and NFKB also showed minimal
effect with dexamethasone treatment when compared to untreated DEN2V -infected cells
(Figure IV -8). In addition , induction of transcription from the IL-8 promoters containing
mutations within the transcription factor binding sites had no significant difference with
dexamethasone treatment of DEN2V - infected HepG2 cells when compared with
untreated DEN2V -infected cells (Figure IV -9).
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These results showed that dexamethasone treatment has no significant effect on
IL-8 expression or activation of c/EBP , AP- l and NFKB from DEN2V -infected HepG2
cells. In contrast, both RANTES secretion and transcription were induced in DEN2V-
infected cells treated with dexamethasone. These results suggest that activation of other
transcription factors that are specific for RANTES expression such as IRFs may be
increased in DEN2V - infected HepG2 cells treated with dexamethasone.
4. Treatment of DEN2V -infected cells with PDTC.
PDTC treatment of DEN2V -infected HepG2 cells had no significant effect on IL-
8 secretion when compared to untreated cells (Figure IV -5). In addition , there was no
virus-induced cell death with PDTC treatment of DEN2V - infected HepG2 cells (Table
IV-2). The effect ofPDTC treatment ofDEN2V-infected cells on IL-8 transcription or
activation of transcription factors was not assessed.
5. Treatment of DEN2V -infected cells witlnndomethacin.
Indomethacin treatment of HepG2 cells induced IL-8 production in both infected
and uninfected cells (Figure IV -5). This result suggests a nonspecific effect on IL-
expression with indomethacin treatment. In contrast to IL-8 production , indomethacin
inhibited RATES secretion in DEN2V -infected HepG2 cells when compared to
untreated cells. These results suggest that indomethacin can inhibit pathways that are
specific to RANTES production , such as factors that can bind to ISRE in the RANTES
promoter.
One caveat to these assays is that HepG2 cells tend to clump in culture. This
made it difficult to obtain high transfection efficiencies. We, therefore , used the reporter
system which allows normalization of the luciferase expression by normalizing values for
ti ,
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background expression of Renila reniformis. 
Although this helped to assess induction of
specific genes, we were unable to continue the assays past day 4 since the luciferase
readings were very low. This was possibly due to multiple divisions of the cells , which
would dilute the signal from the luciferase in cells containing the reporters.
' , "\,
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Table IV -2. Effects of pharmacological inhibitors on cell death and rate of DEN2V
infection in HepG2 cells.
Cell death
Pharmacological Inhibitor DEN2V Uninfected % Infection
SB203580 (10 11M)
+/-
Rolipram (100 11M)
+++
Dexamethasone (250 nM)
+/-
PDTC (250 nM)
Indomethacin (30 11M)
Untreated
a Cell death was assessed microscopically on day 3 post infection.
b Cells were infected at an MOl of 5 with or without inhibitors as described in the
MATERIALS AND METHODS.
C % infection was assessed by flow cytometry on day 6 post infection as described in the
MATERIALS AND METHODS.
+/- equals :S 10% of the monolayer of cells were disrupted.
+ equals 20 - 40% of the monolayer of cells were disrupted.
++ equals 50 - 70% of the monolayer of cells were disrupted.
+++ equals 80 - 100% of the monolayer of cells were disrupted.
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Figure IV-5. IL-8 and RANTES production from DEN2V-infected HepG2 cells
treated with pharmacological inhibitors. HepG2 cells were infected with DEN2V at
an MOl of 5 for 2 hours at 37 C with or without addition of inhibitors as described in
MATERIALS AND METHODS. Supernatants were taken 24 , 72 or 144 hours post
infection for detection of A. IL-8 or B. RANTES protein by ELISA. The data shown is a
representative result from two independent experiments. RP , SB , Dex and Indo represents
rolipram, SB203580 , dexamethasone and indomethacin treated cells , respectively.
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Figure IV-6. IL-8 and RANTES secretion from DEN2V-infected HepG2 cells
treated with pharmacological inhibitors. HepG2 cells were infected with DEN2V at
an MOl of 5 for 2 hours at 37 C with or without addition of inhibitors as described in
MATERIALS AND METHODS. Supernatants were collected 72 or 96 hours post
infection for detection of A. IL-8 or B. RANTES protein by ELISA. RP, SB and Dex
represent rolipram, SB203580 and dexamethasone treated cells , respectively.
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Figure IV-7. Activation of the IL-8 and RANTES promoters in DEN2V-infected
HepG2 cells treated with pharmacological inhibitors. HepG2 cells were transfected
with reporter constructs containing the IL-8 or RANTES promoter. After 24 hours , cells
were infected with DEN2V at an MOl of 5 for 2 hours at 37 C with or without addition
of inhibitors as described in MATERIALS AND METHODS. Celllysates were
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harvested for analysis of luciferase activity at A. 72 or B. 96 hours post infection. The
data were normalized for transfection efficiency based on 
R. reniformis luciferase activity
and expressed as fold induction relative to media for untreated cells. The data are
expressed as mean:! standard deviation from a representative experiment for a minimum
of two separate experiments, each done in triplicate. RP , SB and Dex represent rolipram
SB203580 and dexamethasone treated cells , respectively.
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Figure IV-S. Activation of the transcription factors c/EBP, AP-l and NFKB in
IL-
DEN2V -infected HepG2 cells treated with pharmacological inhibitors. HepG2 cells
were transfected with reporter constructs containing the IL-8 promoter or tandem repeat
binding sites for transcription factors c/EBP , AP- l or NFKB. After 24 hours , cells were
infected with DEN2V at an MOl of 5 for 2 hours at 37 C with or without addition of
J29
inhibitors as described in MATERIALS AND METHODS. Cel1lysates were harvested
for analysis of luciferase activity at A. 72 hours B. 96 hours post infection. The data were
normalized for transfection efficiency based on 
R. reniformis luciferase activity and
expressed as fold induction relative to media for untreated cells. The data are expressed
as mean:! standard deviation from a representative experiment for a minimum of two
separate experiments , each done in triplicate. RP , SB and Dex represent rolipram
SB203580 and dexamethasone treated cells , respectively.
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Figure IV-9. Activation of mutant IL-8 promoters in DEN2V-infected HepG2 cells
treated with pharmacological inhibitors. HepG2 cells were transfected with vector
encoding a reporter gene for wild type , mtc/EBP , mtAP- l or mtNFKB IL-8 promoters
and infected with DEN2V at an MOl of 5 after 24 hours. At A. 72 or B. 96 hours post
infection , luciferase gene activity was measured and data were normalized for
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transfection efficiency based on R. reniformis luciferase activity and expressed as fold
induction relative to media for untreated cells. The data are expressed as mean:! standard
deviation from a representative experiment for a minimum of two separate experiments
each done in triplicate. RP , SB and Dex represent rolipram , SB203580 and
dexamethasone treated cells , respectively.
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C. SUMMARY OF EFFECTS OF INHIBITORS ON IL-8 AND RANTES INDUCTION
BY DEN2V
Table IV -3 summarized the effects of pharmacological inhibitors on DEN2V-
infected HEK293A cells and HepG2 cells. With the exception of indomethacin , we
found only moderate inhibition of IL-8 and RANTES production with the
pharmacological inhibitors tested. However, dexamethasone treatment of DEN2V-
infected HEK293A cells and SB203580 or rolipram treatment of HepG2 cells enhanced
IL-8 and RANTES secretion in DEN2V -infected cells.
Dexamethasone (HEK293A) and rolipram (HepG2) treatment of DEN2V -infected
cells did not increase transcription from the IL-8 or RANTES promoters when compared
to untreated DEN2V-infected cells. Therefore , post transcriptional mechanisms such as
mRNA stability may be involved in the enhanced secretion of chemokines. In contrast
SB203580 treatment of DEN2V -infected HepG2 cells also showed an increase in
transcription from the 1L-8 and RANTES promoters when compared to untreated
DEN2V -infected cells. This suggests that an increase in transcription resulted in the
enhanced secretion of chemokine proteins in SB203580 treated DEN2V -infected cells.
Most of the pharmacological inhibitors tested have been reported to have an effect
on NFKB activation. However, only dexamethasone, PDTC and indomethacin treatment
of DEN2V -infected HEK293A cells inhibited NFKB activation. There was no effect on
NFKB activation in DEN2V -infected HepG2 cells with or without treatment of inhibitors.
In contrast, an increase in activation of AP- l was seen in DEN2V -infected HepG2 cells
treated with SB203580.
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We found significant activation of the wt and mutant IL-8 promoters in DEN2V-
infected HEK293A and HepG2 cells. However, the activation of reporters containing
tandem repeat consensus binding sites for each transcription factor was significantly
lower. The higher level of luciferase activity with the IL-8 reporters could reflect the
contribution of cooperativity between transcription factors within the IL-8 promoter to
enhance transcription from the IL-8 promoter. Previous reports have shown that binding
of NFKB to its cognate site within the IL-8 promoter cooperatively enhances binding of
weakly bound c/EBP (256). In addition , AP- l and NF1d have been reported to interact
with each other and enhance binding to their cognate sites (307). Therefore , the results
from the wt and mutant IL-8 promoters reflect the contribution of multiple transcription
factors for transcription from the IL-8 promoters. In contrast , the results from cells
transfected with the c/EBP , AP- l and NFKB reporters reflect activation of individual
transcription factors and not their effects on neighboring transcription factors during
DEN2V infection with or without pharmacological inhibitors. Although the transcription
factor reporters may suggest activation of a specific transcription factor, it is important to
analyze the effect of the transcription factor within the context of the full IL-8 promoter.
The inhibitors used in this study were added to cells for a relatively longer period
than what has been used in other systems (up to 6 days versus less than 24 hours
respectively). A limitation of this study may be the rate at which the inhibitors are
metabolized in culture.
Overall , these results suggest that the enhanced secretion of chemokines in
DEN2V -infected cells treated with inhibitors may depend on the activation of pathways
that can activate specific transcription factors or post transcriptional mechanisms.
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Table lV-3. Effects of pharmacological inhibitors on DEN2V-infected HepG2 and HEK293A cells.
chemokine secretion chemokine transcription
IL- RANTES
transcription factors
c/EBP AP- NFKB
Cell line Inhibitor IL- RANTES
HEK293A SB203580
rolipram
dexamethasone
PDTC
indomethacin
HepG2 SB203580
rolipram
dexamethasone
PDTC
indomethacin
i or ! = 1.5 to 2 fold difference 
compared to untreated DEN2V infection
ii or H= 2 fold or more difference compared to untreated DEN2V infection
- = no difference when compared to untreated DEN2V infection
ND = not done
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CHAPTER V:
ANALYSIS OF DENGUE VIRAL PROTEINS AND CHEMOKINE
INDUCTION
A. EXPRESSION OF DEN2V NS5 IS SUFFICIENT TO INDUCE EXPRESSION OF
IL-8 BUT NOT RANTES.
Viral proteins such as NS5A and core protein from HCV can induce chemokines
such as IL-8 (9 , 10). We hypothesized that DEN2V protein(s) can induce chemokine
expression in transfected cens.
In order to study the effects of DEN2V proteins on chemokine induction, it was
necessary to clone each of the DEN2V genes into expression vectors. Dengue viral genes
were first cloned into an entry vector, pDONR201 , by homologous recombination using
the Gateway system (Invitrogen) (Figure V -lJ. An 10 clones were sequenced to verify
that no mutations were introduced within the inserted genes by PCR. Several mutations
were detected. The NS 1 clone contained a nucleotide deletion at 2784 (g). The NS3
clone contained a silent mutation at nucleotide 4545 from t c (Ile to Ile) and a
nonconservative mutation at nucleotide 5793 from a g (Asp to Gly). An
nonconservative mutations were corrected by site-directed mutagenesis and the resulting
plasmids were resequenced to verify that the genes contained the correct sequences.
An 10 DEN2V genes were transferred to a CMV driven mammalian expression
vector (pDEST 40 or pDEST47) by homologous recombination. Due to the availability
of antibodies for detection of protein production, the prM and E genes were engineered
with a stop codon at the 3' end. No stop codons were introduced into the remaining
ill
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genes; therefore, these clones would express the V5 epitope and 6X His tag or GFP that
is engineered into the vector.
The plasmids were transfected into HEK293 cel1s and analyzed by flow
cytometry, microscopy or western blot for expression of the appropriate protein. E
protein expression was detected by flow cytometry using the 3H5 monoclonal antibody.
His-tagged NS 1 , and NS5 proteins were detected by flow cytometry using an anti-His
antibody. Expression of V5 epitope tagged or GFP-tagged NS5 protein was also detected
by western blot using an anti-V5 antibody or by confocal microscopy, respectively.
GFP-tagged NS3 protein expression was detected by GFP using flow cytometry or
confocal microscopy. V5- and His-tagged C , prM , NS2A, NS2B , NS4A and NS4B were
not detected at high levels using an anti-V5 or His antibody and flow cytometry. This
could be due to low transfection efficiencies , low expression levels of the protein , or
protein folding that blocked antibody binding to the V5 or His tag.
To define further the mechanism for induction of chemokine production by
DEN2V infection , we studied the effects of expression of individual DEN2V proteins on
chemokine expression. To also test for the possibility that multiple viral proteins and/or
RNA replication might also be required for IL-8 induction , we used a plasmid expressing
a DEN2V replicon under the control of a CMV promoter (415). The plasmids were
transfected into HEK293A cells, and supernatants were collected on day 2. As shown in
figure V- , the replicon induced IL-8 secretion 6-fold over the control plasmid. NS5
also induced secretion of IL-8, with levels 3-fold over the lacZ control plasmid. The gene
containing the DEN2V replicon is at least three times the size of the NS5 gene. Thus , the
amount of plasmid transfected into the cells may be significantly different for the
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DEN2V replicon versus NS5 and therefore , could affect the level of IL-8 expression. The
3- fold increase of IL-8 secretion from HEK293A cells transfected with DEN2V replicon
when compared to cells transfected with the NS5 expression plasmid may be due to an
increase in the level of expression from the DEN2V replicon , resulting in an increase
NS5 expression. Alternatively, cooperative interaction of multiple viral proteins may be
involved in enhanced IL-8 secretion with the DEN2V replicon. In addition , replication
and/or translation of the DEN2V genome may also activate pathways that induce IL-
expression. In contrast, there was no RANTES secretion from cells transfected with
either the NS5- or the replicon-expressing plasmid (Figure not shown).
Increases in the levels of IL-8 mRNA in cells transfected with the plasmids
expressing NS5 or the replicon, measured by quantitative RT-PCR, correlated with the
increases in IL-8 protein secretion (Figure V-2B). These results show that IL-
expression can be induced by expression of tneDEN2V NS5 protein.
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Figure V-I. Gateway cloning of DEN2V genes (Invitrogen). A. Entry clones are
engineered using homologous recombination to insert attB-flanked PCR product into the
entry vector pDONR201 (donor vector) containing attP sites. This replaces the ccdB
gene, which encodes a protein that interferes with 
E. coli DNA gyrase , thereby inhibiting
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the growth of standard E. coli hosts. B. Homologous recombination between attL sites 
the entry c10ne and the attR sites in the mammalian expression vector pcDNA-DEST40
(destination vector) produce the mammalian expression c10nes (expression c1one) which
express the gene of interest with a V5 epitope and a 6XHis tag at the C- terminus of the
protein.
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Figure V -2. NS5 and DEN2V replicon induce IL-8 expression from HEK293A cells.
A. Plasmids expressing DEN2V proteins or a DEN2V replicon were transfected into
HEK293A cells. Supernatants were harvested day 2 post transfection and analyzed for
IL-8 protein by ELISA. The data are an average from three independent experiments and
the error bars represent the standard deviation. There is a statistically significant
difference for fold induction (P -= 0. 02) between NS5 and LacZ and (P -= 0.03) between
the replicon and LacZ using the paired student t-test. B. IL-8 mRNA levels from
HEK293A cells transfected with NS5 plasmid , replicon , or untransfected cells were
assessed by Taqman PCR on Day 2 post transfection. Results are normalized to
untransfected cells = 100.
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B. DEN2V NS5 AND REPLICON DO NOT ACTIVATE TRANSCRIPTION FROM
ISRE OR THE RANTES PROMOTER.
The RANTES promoter contains binding elements for transcription factors NFKB
and IRF-3 (276 428). IRF-3 has been shown to bind to the ISRE domain in the
RANTES promoter to induce RANTES expression during viral infection (276). We
wanted to analyze the ability of NS5 and replicon to activate the interferon-stimulated
regulatory element (ISRE), as well as RANTES and IL-8 promoters (Figure V -3). As
previously shown , overexpression of the IKK-related kinase TBKI induced transcription
from both the ISRE and RANTES promoters (positive control). Similarly,
overexpression of Mal , the TLR4 adaptor molecule , induced transcription from the IL-
promoter (positive control). NS5 and the DEN2V replicon induced transcription from the
IL-8 promoter. However, neither NS5 nor the dengue replicon activated ISRE or induced
the RANTES promoter.
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Figure V-3. NS5 and DEN2V replicon do not activate the ISRE or RANTES
ISRE RANTES
promoters. HEK293A cells were transfected with a vector containing a reporter gene for
ISRE, RANTES or IL-8 promoters and cotransfected with an expression vector for NS5
or replicon. After 24 hrs , luciferase reporter gene activity was measured and data were
normalized for transfection effciency based on R. reniformis 
luciferase activity and
expressed as fold induction relative to cells transfected with pcDNA3. 1 for each
construct. There is a statistically significant difference 
(P:S 01) between NS5 (100 ng)
or the replicon (100 ng) and pcDNA3. 1 transfected cells for IL-8 reporters using the
student t-test. The data are expressed as mean:! standard deviation from a representative
experiment for a minimum of two separate experiments , each done in triplicate.
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C. ACTIVATION OF TRANSCRIPTION FACTORS BY DEN2V NS5 AND
REPLICON.
The transcription factors involved in IL-8 mRNA induction include c/EBP , AP-
and NFKB (251) To identify the transcription factors that are induced by NS5 or the
replicon , we used luciferase reporter constructs with promoters that contain multiple
copies of binding sites for c/EBP , AP- l or NFKB. NS5 induced c/EBP driven
transcription 7 -fold and AP- l 5- fold; NFKB was induced less than 2- fold over the control
plasmid (Figure V -4). The replicon had a similar profile in the induction of c/EBP (7
fold), AP- 1 (3 fold) and NFKB (less than 2). These results suggest that c/EBP and AP-
are activated by expression of NS5 or the replicon.
However, as previously mentioned in CHAPTER IV , there is cooperativity among
transcription factors within the IL-8 promoter. Therefore , the activation of transcription
factors can have a significant effect on neighboring transcription factors, resulting in
enhanced IL-8 expression. To further assess the importance of each of these transcription
factors for the induction of IL-8 by NS5, reporter constructs containing mutations in the
IL-8 promoter binding sites for c/EBP (mtc/EBP), AP- l (mtAP- 1) or NFKB (mtNFKB)
(416) were studied. As shown in figure V- , a mutation in the c/EBP binding site within
the IL-8 promoter reduced activation by NS5 expression -50% when compared with the
wild type (wt) 1L-8 promoter. A mutation in the NFKB binding site had minimal effect
(- 20 % reduction) on the induction of IL-8 transcription by NS5 when compared to the
wt IL-8 promoter. However, a mutation in the AP- l binding site enhanced NS5 driven
transcription from the 1L-8 promoter by -20%. These results suggest that c/EBP is a
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dominant component in the induction of the IL-8 promoter by NS5. In contrast, AP- l did
not have a predominant effect on IL-8 induction by NS5 and may even be inhibitory.
It has previously been reported that NS5 contains a nuclear localization signal and
localizes to the nucleus during the later stages of DEN2V infection r 1191. We wanted to
assess whether the NS5 in this study localized to the nucleus at the time of IL-
induction. NS3 , on the other hand, is not known to localize to the nucleus and was used
as a negative control. We used constructs that expressed either NS3 or NS5 with a GFP
tag. As seen in figure V - , NS5 localized to the nucleus at 24 hours post transfection
whereas NS3 remained in the cytoplasm. It is thought that binding of NS3 to NS5 as part
of the replication complex retains NS5 in the cytoplasm. Upon hyperphoshphorylation of
NS5 , NS3 is released exposing the nuclear localization signal on NS5 and allowing NS5
to localize to the nucleus (119). Since the NS5 expression plasmid was not cotransfected
into cells with other components of the replication complex, it is possible that the nuclear
localization signal within NS5 is able to bind the the importin receptors immediately.
Thus, no cytoplasmic NS5 was seen by confocal microscopy in this experiment as has
been seen in cells infected with DEN2V.
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Figure V -4. Transcription factors activated by NS5 and DEN2V replicon. HEK293A
cells were cotransfected with vector encoding a reporter gene for IL- , clEBP , AP- , or
NFKB and an expression vector for NS5 or DEN2V replicon. After 24 hours , luciferase
gene activity was measured. Data were normalized for transfection efficiency based on
R. reniformis luciferase activity and expressed as fold induction relative to cells
transfected with pcDNA3.1 for each construct. There is a statistically significant
difference (P:: 05) between NS5 (lOa ng) or the replicon and pcDNA3. 1 transfected
cells for IL- , clEBP and AP- l reporters using the student t-test. The data are expressed
as mean:! standard deviation from a representative experiment for a minimum of two
separate experiments, each done in triplicate.
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Figure V -5. Effect of NS5 expression on transcription from mutated IL-8 promoter
reporter constructs. HEK293A cells were cotransfected with vector encoding a reporter
gene for wild type , mtclEBP, mtAP- , and mtNF1d IL-8 promoters and an expression
vector for NS5. After 24 hours, luciferase gene activity was measured. Data are
normalized for transfection efficiency based on R. reniformis luciferase activity and
expressed as fold induction relative to cells transfected with pcDNA3. 1 for each
construct. MtcIEBP , mtAP- , and mtNFK:B represent the 133-luc IL-8 reporter plasmid
with point mutations in the cIEBP , AP- , and NFK:B binding sites. There is a statistically
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significant difference (P:S 05) between NS8 (80 ng) and pcDNA3. 1 transfected cells
for IL- , mtclEBP, mtAP- I and mtNFKB reporters using the student t-test.The data are
expressed as mean:! standard deviation from a representative experiment for a minimum
of two separate experiments , each done in triplicate.
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Figure V -6. Cellular localization of DEN2V NS3 and NS5 proteins. HEK293A cells
were transfected with plasmids expressing GFP-tagged NS3 (A-C) or NS5 (D-
proteins. Cells were fixed on a glass coverslip with ethanol and nuclear structures were
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stained with DAPI. A and D show DAPI staining (blue), Band E show GFP expression
(green), and C and G show the overlay of DAPI stain and GFP expression for NS3 and
NS5 transfected HEK293A cells , respectively. The center image, F, is the cell seen in
phase contrast microscopy.
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D. ANALYSIS OF TRANSCRIPTION FACTORS INDUCED BY EXPRESSION OF
DEN2V PRM-
We did not detect induction oflL-8 expression in cells transfected with the
DEN2V prM or DEN2V E proteins separately (Figure V-2A). We considered the
possibility that expression of both proteins together, which leads to the formation of
virus-like particles (86), might have effects on chemokine expression not seen with either
protein alone. Therefore , we transfected HEK293A cells with a plasmid containing the
DEN2V prM-E genome segment. DEN2V E protein was detected in both celllysates and
supernatants of HEK293A cells transfected with the prM-E expression plasmid by
western blot (Figure V -7). Since the E protein is not generally secreted from the cell
detection of E in the supernatants suggests that viral-like particles were released from the
cell. As mentioned in the section D: Virus Structure and Composition, the E protein is a
glycoprotein. The double band seen in figure V -7 in the prM-E lysates may be due to
different levels glycosylation of E.
Transfection of prM-E induced IL-8 secretion in HEK293A cells but was not
significantly different than media (data not shown). To analyze the effect prM-
expression would have on IL-8 transcription , we cotransfected the prM , E and prM-
expression plasmids into HEK293A cells along with the IL-8 reporter construct. The
expression of prM-E activated transcription from the IL-8 promoter 2 fold over prM or E
transfected HEK293A cells (Figure V-8). To characterize the effect ofprM-E expression
on activation of transcription factors constructs , the prM-E expression plasmid was
cotransfected with reporters containing tandem repeat binding sites for the transcription
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factors c/EBP, AP- l and NFKB. The c/EBP, AP- I and NFKB luciferase reporters were
activated approximately 2 5 and 3 fold over the control , respectively (Figure V-9).
To analyze the importance of c/EBP , AP- I and NFKB within the context of the
IL-8 promoter, we cotransfected the prM-E expression plasmid with mutant IL-
promoter constructs used in previous experiments. Analysis of mutant IL-8 promoters
showed a slight decrease in IL-8 transcription by prM-E expression when the c/EBP site
is mutated (Figure V - 10). In addition, activation ofIL-8 transcription by prM-
expression was not significantly different in the IL-8 reporter construct containing a
mutation in the AP- l binding site when compared to the wt IL-8 promoter. In contrast
the mtNFKB reporter had a -50% increase in luciferase activity when compared with the
wt IL- 8 promoter suggesting an inhibitory effect for NFKB. This suggests that NFKB
may have an inhibitory role in transcription from the IL-8 promoter. Overall , these results
show a role for c/EBP , AP- l and NFKB in the induction of IL-8 by prM-E expression.
It is important to note that the level of activation from the wt and mutant IL-
reporters and the c/EBP, AP- l and NFKB reporters with the prM-E expression plasmid
was lower than what was seen with NS5 expression plasmid. This could be due to a
lower level prM-E expression from the plasmid or a lower amount of prM-E that is
retained in the cell. As seen in figure V- , prM-E is released into the supernatants of
transfected cells by 24 hours post transfection, which is when transcription from the IL-
promoter is activated.
We wanted to know whether formation of virus-like particles could also induce
the transcription from promoters containing an ISRE site. We cotransfected the prM-
expression plasmid with the IPIO or RANTES promoter constructs or an ISRE driven
' '
153
promoter. We found that prM-E expression did not induce any constructs containing an
ISRE binding site (Figure V 11). These results suggest that virus-like particle formation
and release did not induce transcription factors such as IRFs that bind and activate
transcription through the ISRE.
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Figure V -7. Detection of E expression by western blot. Vero cells were infected with
DEN2V at an MOl of 1 and cells were harvested 48 hours post infection. HEK293 cells
were transfected with the prM-E expression plasmid. After 24 hours , supernatants and
cells were harvested for western blot analysis. The E protein was detected using the 3H5
antibody as described in MATERIALS AND METHODS.
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Figure V-So prM-E induces transcription from the IL-S promoter. HEK293A cells
were cotransfected with a vector encoding a reporter gene for IL-8 and plasmids
expressing DEN2V prM , E or prM-E. After 24 hours , luciferase gene activity was
measured. Data are normalized for transfection efficiency based on R. reniformis
luciferase activity and expressed as fold induction relative to cells transfected with
pcDNA3. 1 for each construct. There is a statistically significant difference for fold
induction (P oe 0.01) of luciferase activity between prM-E and pcDNA3. 1 transfected
cells using the paired student t-test. The data are expressed as mean:: standard deviation
from a representative experiment for a minimum of two separate experiments , each done
in triplicate.
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Figure V-9. Transcription factors activated by prM-E. HEK293A cells were
cotransfected with vector encoding a reporter gene for IL- , c/EBP, AP- , or NFKB and
the plasmid expressing DEN2V prM-E. After 24 hours , luciferase gene activity was
measured. Data are normalized for transfection efficiency based on R. reniformis
luciferase activity and expressed as fold induction relative to cells transfected with
pcDNA3. 1 for each construct. There is a statistically significant difference for fold
induction (P -: 0.05) of luciferase activity between prM-E and pcDNA3. 1 transfected
cells for AP- l and NF1d reporters using the paired student t-test. The data are expressed
as mean:! standard deviation from a representative experiment for a minimum of two
separate experiments , each done in triplicate.
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Figure V-lO. Effect of prM-E expression on transcription from mutated IL-
promoter reporter constructs. HEK293A cells were cotransfected with vector
encoding a reporter gene for IL- , mtc/EBP, mtAP- , and mtNFKB IL-8 promoters and
an expression vector for DEN2V prM-E. After 24 hours , luciferase gene activity was
measured. Data are normalized for transfection efficiency based on R. reniformis
luciferase activity and expressed as fold induction relative to cells transfected with
pcDNA3. I for each construct. Mtc/EBP , mtAP- , and mtNFKB represent the 133-luc IL-
8 promoter plasmid with point mutations in the c/EBP, AP- , and NFKB binding sites.
There is a statistically significant difference for fold induction (P oe 0.02) of luciferase
; I activity between prM-E and pcDNA3. I transfected cells for mtc/EBP , mtAP- I and
':,
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mtNFKB reporters using the paired student t-test. In addition , there is a statistical
significant for fold induction (P 0( 0.04) of luciferase activity for prM-E transfected cells
between wt IL-8 and mtc/EBP or mtNFKB reporters. The data are expressed as mean :!
standard deviation from a representative experiment for a minimum of two separate
experiments , each done in triplicate.
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Figure V-ll. prM-E does not activate the ISRE, RANTES or IPIO promoters.
HEK293A cells were cotransfected with a vector containing a reporter gene for ISRE
RANTES or IPIO and the prM-E expression plasmid. After 24 hours , luciferase reporter
gene activity was measured. Data were normalized for transfection efficiency based on
R. reniJormis luciferase activity and expressed as fold induction relative to cells
transfected with pcDNA3. 1 for each construct. The data are expressed as mean :!
standard deviation from a representative experiment for a minimum of two separate
experiments, each done in triplicate.
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CHAPTER VI:
DISCUSSION
A. CHEMOKINE PROFILE OF DENGUE INFECTED CELL LINES AND PRIMARY
CELLS
Our results demonstrate that dengue virus infection of diverse human cell lines
can induce the production of multiple chemokines in vitro. This finding is similar to
previous results from other investigators (4 , 396 , 398 401). However, our study
indicates that DEN2V infection can induce a unique profile of chemokine expression in
each cell type tested. The differences in chemokine expression in different cell types
may be partly explained by variable types of transcription factors that are expressed (429-
431). The chemokine expression peaked late, three to five days after dengue virus
infection , in all the continuous cell lines we tested (Table III- I). Possible explanations
for the delay in chemokine expression could be a need for the virus to reach a threshold
of viral load to induce chemokines , a need for transcription factors involved in
chemokine induction to be induced, or a time delay in viral protein translocation into the
nucleus (discussed further below).
A similar pattern of late chemokine induction was reported in DENV infection of
primary monocytes/macrophages , which showed peak levels at least 48 hours post
infection (398). In contrast, we have shown that dendritic cells expressed IL- , RANTES
MCP- , MIP- Ia and MIP- as early as 24 hours post infection (Tables 1II- 6). The
earlier chemokine production in dendritic cells could reflect their role as sentinels of the
immune system (431).
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We also showed an increase in steady-state chemokine mRNA levels over time
during DEN2V infection of cell lines (Figure III-2). Although we have not excluded the
possibility that increased chemokine secretion is due to mRNA stabilization , as has been
reported with respiratory syncytial virus-induced RANTES expression or adenovirus-
induced IL-8 expression (432 433), we have shown that transcription from the IL-
promoter was induced by DEN2V infection.
B. ROLE OF TRANSCRIPTION FACTORS IN CHEMOKINE INDUCTION DURING
DEN2V INFECTION
DEN2V infection of HEK293A cells induced NFKB-driven transcription (Figure
III- II). Interestingly, NFKB was not activated in HepG2 cells by DEN2V infection. 
were able to induce NFKB using PMA and ionomycin treatment in HepG2 cells
suggesting that these cells are not deficient inNFId3. Therefore the results suggest that
DEN2V does not activate NFKB in HepG2 cells. Similarly, a recent paper looked at the
activation of NFKB by analyzing levels of IKB Ser32 phosphorylation in another hepatic
cell line , Huh- , infected with DENV (427). The authors found no IKB phosphorylation
in Huh-7 cells infected with DENV at 48 hours post infection. These results suggest that
NFKB is not activated in liver cells infected with DENV.
In contrast, this study shows that transcription from the AP- I promoter was
induced in DEN2V -infected HepG2 cells (Figure III- II). AP- I activation was also seen
in DEN V infection of Huh-7 cells (427). Studies have shown that AP- I can interact with
NFKB or clEBP to enhance transcription of genes such as TNFa and IL-8 (426 , 434).
Therefore , AP- I activation could cooperatively interact with clEBP to enhance
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transcription factor binding to the chemokine promoter and induce chemokines in DENY
infected HepG2 cells without activation of NFKB.
These findings with DENY infection of hepatic cell lines can be compared with
the results of similar studies with HCY , a distantly related member of the family
Flaviviridae. HCY coinfection is found in approximately one third of HIY -infected
individuals in the United States (435), and these co-infected patients suffer from
accelerated HCY disease progression (436). An analysis was done of IL-8 secretion in
HepG2 cells costimulated with HCY E2 and HIY gp 120 to simulate coinfection of HIV
and HCY in vivo (437). These authors found that IL-8 production was induced through
an NFKB independent mechanism. Additionally, AP- l binding to DNA was enhanced.
Another study found that expression of the HCV core protein activated AP- , NF1d
RANTES and MCP- l reporters in HeLa cells but inhibited transcription from these
reporters in Huh-7 and HepG2 cells , suggesting that there are differences in the
transcriptional response to viral proteins in various cell types (438). In contrast to
chronic infection with HCV , liver involvement during DENV infection occurs during the
febrile period and is transient (143). However, DENV shows many similarities to HCY
in the induction of chemokines using viral proteins and may use similar pathways for
induction of IL-8 in hepatic cells that do not require NF1d.
It has been established that TNF can induce IL-8 through an NFKB-dependent
pathway in many cell types including liver cells (439). However, a study looking at the
effects of a proteasome inhibitor (MG 132) on TNF induced IL-8 production in HepG2
cells and fetal hepatocytes found an increase in IL-8 protein and mRNA levels that
occurred independent of NFK:B (440). The increase in IL-8 correlated with enhancement
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of AP- I binding to the DNA , an increase in JNK activation and inhibition of NFKB.
Another study found that ligation through the Fcy receptor on Thp- l cells induced IL-
MIP- la and MIP- (441) This effect occurred mainly through activation of clEBP.
These results indicate that IL-8 induction can occur by other pathways than NFKB
activation such as c/EBP and/or AP- I activation.
C. PHARMACOLOGICAL INHIBITORS
NFKB plays a predominant role in chemokine and cytokine induction in many
experimental systems (304). Similarly, studies reported that NFKB played a major role in
DENV induced IL-8 production (4 6) and our data in HEK293A cells yielded similar
conclusions. We , therefore , wanted to assess the effects of pharmacological drugs that
have been shown to inhibit NFKB and cytokines on IL-8 and RANTES production during
DEN2V infection. The results from these studies were surprising. In a number of cases
drug treatment enhanced IL-8 and RATES secretion during DENV infection (e.
dexamethasone treatment in HEK293A cells or SB203580 and rolipram treatment in
HepG2 cells , Figures IV- l and IV-5 , respectively).
In HEK293A cells , all of the drugs tested , with the exception of dexamethasone
inhibited IL-8 and RANTES secretion (Figure IV-I). Interestingly, dexamethasone
enhanced secretion of IL-8 and RANTES on day 3 and 4 post infection. In contrast
transcription from the IL-8 and RANTES promoter was inhibited when compared to
untreated DEN2V infected HEK293A cells (Figure IV-2). Dexamethasone has been
reported to inhibit both the JNK pathway and NFKB (362 , 442). Our results also showed
an inhibition of NFKB activation in dexamethasone treated HEK293A cells infected with
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DEN2V when compared to untreated DEN2V -infected cells. In contrast , transcription
from the AP- I and c/EBP promoters was unaffected in DEN2V -infected HEK293A cells
treated with dexamethasone. These results suggest that the increase in IL-8 secretion in
DEN2V -infected HEK293A cells treated with dexamethasone may be due to an increase
in mRNA stability. An analysis of mRNA decay in the presence of actinomycin D could
show whether the half life of chemokine mRNA has changed with dexamethasone
treatment in comparison with untreated DEN2V infected cells.
Although SB203580 and rolipram enhanced IL-8 and RANTES secretion by day
6 post infection in HepG2 cells , they appeared to use different pathways to achieve this
effect. The p38 MAPK pathway, inhibited by SB203580, has been implicated in
increasing mRNA stability (304). Therefore , inhibiting p38 MAPK would be expected to
decrease the half life of IL-8 and RANTES mRNAs resulting in a decrease in protein
levels. However, we found an increase in IL..8 and RANTES secretion. In addition , we
found an increase in IL-8 transcription by day 3 post infection with treatment of
SB203580 in DEN2V-infected HepG2 cells (Figure IV-2). This indicates that the
increase in protein production in DEN2V-infected HepG2 cells treated with SB203580
was likely due to an increase in the transcription of IL-
Rolipram has been found to specifically inhibit PDEIV , which results in an
increase in intracellular levels of cAMP (443). High levels of cAMP in the cell can
activate many pathways including induction of protein kinase A (PKA) and cAMP
response elements (CRE) within promoters (443). CRE-binding proteins have been
found to play an important role in the physiology of the pituitary gland , in regulating
spermatogenesis , in the response to circadian rhythms , and in the molecular basis of
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memory (444). Therefore , rolipram may have a more global effect on cell function , and
it is , therefore , more difficult to delineate individual pathways involved in the induction
of chemokines. A previous study showed that treatment of HIV -infected T cells with
rolipram decreased TNFa and IL- I 0 production (359). The authors attributed the
cytokine suppression to the inhibition of NFKB and NF A T. The results from our study
show that treatment with rolipram enhanced IL-8 and RANTES protein expression in
DEN2V -infected HepG2 cells but not in HEK293A cells. In contrast, transcription from
the IL-8 promoter was inhibited by rolipram (Figure IV -7). There was little difference in
the activation of c/EBP , AP- l or NFKB reporters between rolipram treatment of DEN2V
infected HepG2 cells and untreated cells (Figure IV-8). These results suggest that post-
transcriptional mechanisms, e.g. mRNA stability or translation , are responsible for the
increase of chemokine protein levels.
The results of our experiments with pharmacological inhibitors in DEN2V
infected HepG2 and HEK293A cells raise questions about how these drugs would
potentially affect proinflammatory chemokines over an extended period of time. Most
other studies using the pharmacological inhibitors tested here have been performed over
relatively short term incubation times (0: 24 hours). Although these drugs may inhibit
certain pathways initially, the results from the present study indicate that prolonged use
during DENV infection may lead to the activation of pathways that could increase the
inflammatory response via chemokine induction in certain tissues such as the liver. 
suppression of DENV -induced chemokine secretion is a desirable goal of therapy in
DENV infections , and if our results with continuous cell lines are representative of the
effects that could be expected in vivo then treatment of dengue patients with the drugs
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tested in this study could have detrimental consequences and perhaps enhance disease
severity.
D. NS5 AND IL-8 INDUCTION
The observation that individual proteins of HCV , HIV and other viruses can
induce chemokine production led us to study whether individual DEN2V proteins have a
similar function. Our findings of IL-8 induction by NS5 reveal a novel mechanism for
induction of chemokine production by DEN2V. The DENV NS5 is a large
multifunctional protein containing an S-adenosyl-methionine(SAM)transferase domain in
the N-terminal region (445) and a RNA dependent RNA polymerase domain in the C-
terminal region (113 446). NS5 has been shown to be differentially phosphorylated at
serine and threonine residues and located in both the cytosol and the nucleus (119, 447
448). Two nuclear localization signals , bNLS and a/NLS, have been found in the
interdomain region of NS5 , and are recognized by importin band a/b, respectively (449
450). The bNLS region of NS5 was found to overlap with the binding site of NS3. In the
late stage of infection, NS5 becomes hyperphosphorylated and it is thought to dissociate
from NS3 , exposing the bNLS (119), (450). The function of nuclear localized NS5 has
not been identified. However, the timing of IL-8 secretion late in infection correlates
with movement of NS5 to the nucleus (119). It is possible that nuclear NS5 can bind
directly or indirectly to the IL-8 promoter to induce gene expression. Chromatin
immunoprecipitation (ChIP) may be useful in determining whether NS5 can interact
directly with the IL-8 promoter.
It has been shown that different strains of DEN2V (e.g. American versus Asian
genotypes) are associated with varying degrees of disease severity (29). Previous
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research compared sequences of the ' Asian ' genotype of DEN2V , which is associated
with DHF, and the ' American ' genotype , which appears to be incapable of causing DHF
(451). Five of the eight consistent amino acid differences between these two genotypes
in the nonstructural proteins were located in the N terminus of NS5. We constructed the
NS5 expression plasmid from the infectious cDNA clone of Polo et al (419), derived
from the DEN2V strain New Guinea C , a member of the ' Asian ' genotype. It wil be
interesting to determine whether sequence differences within NS5 could change the
ability of the protein to induce IL-
E. EFFECTS OF VIRAL REPLICATION AND VIRAL-LIKE PARTICLES ON GENE
EXPRESSION
We also found that expression of the DEN2V prM-E induced IL-8 secretion and
transcription. Our analysis of prM-E indicated that activation of c/EBP, AP- l and NFKB
were equally important for IL-8 induction (Figure V- I 0). This pattern was different
from that seen with expression of NS5 or the DEN2V replicon. These results suggest that
packaging of the virus may be one of the DENV -induced pathways that require NFKB
activation to induce IL-8 expression.
RANTES gene expression requires binding of IRFs to the ISRE element along
with activation of c/EBP , AP- l and NFKB (276). DEN2V infection induced activation of
the ISRE element whereas expression of NS5 , prM-E or the replicon did not. IRFs are
important in regulating expression of Type I IFN genes , IFN-stimulated genes (ISGs) and
other cytokines and chemokines such as RANTES and IPIO (452). Reports have shown
that replication of RNA viruses generates dsRNA intermediates that are recognized by
TLR3 and non TLR3 mechanisms (453). TLR3 activation results in nuclear localization
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of IRF3 (454). Recently, Collins et al reported that enveloped RNA viruses (Newcastle
Disease virus and Sendai virus) were able to induce IFN stimulated genes (ISGs) such as
ISG56 and IPIO without viral replication (455). In our study, the RANTES and IPlO
promoters were not induced by DEN2V prM-E expression or the replicon but induction
did occur with DEN2V infection. In addition , UV -inactivated DEN2V did not induce
IPlO or RANTES induction. These results suggest that a different stage of the DENV life
cycle other than replication and/or translation of the genome or virion packaging and
release are involved in activation of ISGs during DENV infection. Alternatively, both
viral entry and replication may be required to induce genes containing ISRE elements
during DENV infection.
F. MODEL OF IL-8 INDUCTION BY DEN2V
Expression of the core and NS5A proteins of HCV were able to activate
transcription from the IL-8 promoter (9 , 10). Deletion experiments found that the C
terminus region of NS5A , which contains the NLS , was responsible for the induction of
IL-8. Polyak et al also found that NS5A activated IL-8 transcription through AP- l and
NFKB , whereas , the c/EBP site was inhibitory (9). Qadri et al reported that HCV NS5A
induction of AP- l occurred through an increase in the expression of c-jun subunits while
there was no effect on c-fos protein levels (456). Similarly, the induction of AP- l has
been reported for other viruses. HIV Tat protein can induce c-Jun through an oxidant
dependent mechanism (457) and hepatitis B protein HBx can induce AP- l through the
ERK and JNK pathway (458). The present study has shown that several steps in the
DEN2V viral life cycle - RNA replication, production of virus particles and the
expression of individual viral proteins - activate a unique profile of transcription factors
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that can induce the expression of IL-8 by a DEN2V -infected cell. The NS5 protein can
induce IL-8 by c/EBP and AP- I activation. In addition , production of viral like particles
can induce IL-8 mainly through NFKB and AP- I. DEN2V infection can induce IL-
mainly through activation of NFKB and AP- l. These multiple pathways for the induction
of IL-8 can ensure that IL-8 is expressed throughout the viral life cycle (Figure VI- I).
Previous studies had reported that NFKB plays a major role in DENV -induced IL-
8 production (4, 6). However, the inhibitors that enhanced IL-8 and RANTES protein
levels in the supernatants of DEN2V -infected cel1s activated AP- I and possibly c/EBP
driven transcription. NFKB activation was not enhanced when compared to untreated
DEN2V -infected cel1s in these same conditions suggesting that it has a minor role in IL-
and RANTES induction with drug treatment. As noted earlier, this temporal pattern of
IL-8 induction correlates with the movement of NS5 into the nucleus. In addition, the
predominant role of AP- I and possibly c/EBP in IL-8 induction by DEN2V in the
presence of rolipram, SB203580 and dexamethasone was also seen when HEK293A cells
were transfected with NS5. It is possible that nuclear NS5 plays a role in the increase in
IL-8 expression in the presence of these drugs by activating c/EBP and AP-
G. IL-8 EFFECTS ON INNATE IMMUNITY
IL-8 induction has been found to counteract the antiviral effects of IFNa and
enhance viral replication of many viruses including EMCV , poliovirus , CMV and HIV
459, 460). HCV core protein , EI and NS5A protein have been shown to counteract
the antiviral IFN response (9 461). One of these mechanisms is the induction of IL-8 by
the NS5A protein (9). The induction of IL-8 by NS5A inhibited the effect of IFNa on
EMCV viral replication.
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DENY proteins have recently shown similar effects on innate immunity as seen
with HCY. DENY NS4B and, to a lesser extent , NS2A and NS4A , inhibited IFN-
induced signal-transduction by interfering with ST A Tl function in a monkey kidney ce11
line (111). Another study using a myeloid cell line (K562) that stably expresses the
dengue replicon found that DENY non structural proteins reduced intrace11ular ST A T2
levels (230). Our data indicate an indirect mechanism to counter antiviral effects of
IFNa through the induction of IL-8 by NS5. IL-8 can inhibit the induction of an antiviral
state by IFNa in neighboring uninfected cells, thereby a110wing viral progeny to infect
these cells (8). DENY may use this mechanism to counteract antiviral effects of innate
immunity in conjunction with previous reported pathways, thus allowing further
dissemination of the virus in neighboring uninfected cells.
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Figure VI-I. Model for IL-8 induction by DEN2V and its effect on virus
propagation. Multiple pathways for IL-8 expression are induced during DEN2V
infection (left). The NS5 protein can induce IL-8 by c/EBP and AP- l activation, whereas
production of viral like particles (prM-E) can induce IL-8 mainly through NFKB and AP-
1. DENV infection induces IL-8 mainly through activation of NFKB and AP- l. Binding
of IL- 8 to its receptor activates signaling through G proteins, Ga and 'Y (right).
Activation of IL-8 receptor signaling inhibits activation of the Jak/Stat pathway and thus
counteracts the antiviral effects of IFNa. The inhibition of the IFNa pathway creates a
less hostile environment for viral infection, which wil facilitate infection of neighboring
cells with progeny virus.
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H. IL-8 EFFECTS DURING SECONDARY DENY INFECTIONS AND
DISEASE PATHOGENESIS
IL-8 has been shown to be elevated in sera and PBMC of patients with more
severe dengue disease , DHF (394, 395). In addition , we have shown that the mean levels
of IL-8 mRNA in PBMC are higher later during DENY infection , although there were no
statistically significant differences between DF and DHF patients. This may be due to
the lack of higher mean viremia in the DHF patients compared to DF patients in this
sample of subjects (199).
IL-8 can be induced by cytokines , which include IL- l and TNF (251) TNFa and
IL- are induced in DF and DHF patients and may induce low levels ofIL-8 (51 67).
Recently, a study showed that stable transfections with HCY NS5A and core protein
induced RANTES in Chang cells , a liver cell line (462). When these HCV protein-
transfected cells were stimulated with IL- , TNFa and IFNy, they induced significant
levels of levels ofIPI0 and Mig protein and mRNA when compared to mock transfected
cells. By analogy, stimulation of DEN2V-infected cells by cytokines in vivo could
further enhance the induction of chemokines such as IL-8 by NS5 or other viral proteins
and contribute to the pathogenesis of DEN2V infection.
We have shown that NS5 can induce activation of c/EBP and that c/EBP plays an
important role in the induction of IL-8. c/EBP was originally identified as a DNA-
binding protein responsible for IL- l-stimulated IL-6 induction (309). The consensus
binding site for c/EBP has been found in promoter regions of several proteins involved in
acute phase reactions, which includes IL-8 and IL-6 (309). It would be interesting to
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determine if NS5 could induce IL-6 expression through the c/EBP consensus site in
addition to IL-
A recent paper has shown that IL-S can alter the cytoskeleton and tight junctions
of microvascular endothelium and change the permeability of the endothelial monolayer
(5). Moreover , elevated levels of IL-6 can also increase permeability of the endothelial
barrier in vitro (3, 5). The combined expression of IL-6 and IL-S due to activation c/EBP
by DEN2V NS5 may increase the likelihood of plasma leakage in DENV infected
patients.
Primary DENV infections can induce T cells that respond to antigens specific to
the infecting serotype as well as T cells that respond to heterologous serotypes (5S).
During secondary DENV infections, these memory T cells would have a lower threshold
for activation than naive T cells and the potential to respond more rapidly. This effector
memory T cell response to the secondary DENV infection is thought to produce
inflammatory cytokines that can induce plasma leakage (463).
Recently, the receptor for IL- , CXCRl, was shown to be expressed on terminally
differentiated effector memory CDS+ T cells , which express high levels of IFNy and
cytotoxic molecules upon activation (464 465). Incorporating this finding to the
laboratory s model on DHF pathogenesis that was mentioned previously, it is possibl
that expression of IL-S from infected cells can recruit DENV -specific memory CDS+ T
cells that express CXCRl to the sites of infection. These T cells would 
rapidly produce
inflammatory cytokines and thus, increase the chances of more severe dengue disease
(Figure VI-2).
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Previously, it has been reported that DHF patients tend to have a higher viral
burden early in infection which may correlate with increased NS5 expression (144 466).
The increase in NS5 may elevate levels of IL-8 and contribute to the pathogenesis seen in
patients with DHF.
Overall , IL-8 is a chemoattractant for cells expressing CXCR 1 such as
neutrophils and cytotoxic memory CD8+ T cells. IL-8 has been shown to increase the
permeability of an endothelial monolayer directly. Both of these mechanisms may playa
role in plasma leakage that occurs in DHF. Furthermore , IL-8 can subvert the innate
immune defense by inhibiting the antiviral effects of IFNa, thereby, potentially
enhancing viral dissemination. Through a combination of these effects , enhanced IL-
production by DENY may increase the likelihood of more severe disease particularly
during secondary DENY infection.
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Figure VI-2. Modifed model for DHF pathogenesis. This is a model of a previous
figure (Figure 1-3) showing effects ofIL-8 on DENV pathogenesis. Production ofIL-
from DENV-infected cells can directly increase the permeability of the vascular
endothelium (orange arrow). In addition , DENV-specific CD8+ T cells that express
CXCRI can be recruited to the site of infection by IL-8 (green arrow). These
mechanisms can increase the pathogenesis during DENV infection.
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I. SUMMARY
The results described in this thesis have provided a better understanding of the
mechanisms by which DEN V induces chemokines. The important observations made in
this thesis can be summarized as follows:
1. DEN2V can infect many cell lines including liver cells , kidney cells , monocytic cells
endothelial cells and as well as monocyte-derived dendritic cells in vitro.
2. DEN2V infection can induce unique chemokine profiles for each cell type.
3. DEN2V can activate different transcription factors for HepG2 cells and HEK293A
cells.
4. The use of pharmacological inhibitors of cytokine production on DEN2V infected
cells can paradoxically enhance the production of chemokines depending on the cell type
infected.
5. DEN2V protein NS5 can induce expression of IL-8 through activation of clEBP, and
AP-
6. Production of DEN2V virus-like particles and replication and/or translation of
non structural proteins can also induce IL-8 expression.
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